WO2011133953A1 - Compositions pharmaceutiques et leurs administrations - Google Patents

Compositions pharmaceutiques et leurs administrations Download PDF

Info

Publication number
WO2011133953A1
WO2011133953A1 PCT/US2011/033689 US2011033689W WO2011133953A1 WO 2011133953 A1 WO2011133953 A1 WO 2011133953A1 US 2011033689 W US2011033689 W US 2011033689W WO 2011133953 A1 WO2011133953 A1 WO 2011133953A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
column
degrees
component
vol
Prior art date
Application number
PCT/US2011/033689
Other languages
English (en)
Inventor
Fredrick F. Van Goor
Rossitza Gueorguieva Alargova
Tim Edward Alcacio
Sneha G. Arekar
Hayley Marie Binch
Martyn Curtis Botfield
Lev Tyler Dewey Fanning
Peter Diederik Jan Grootenhuis
Dennis James Hurley
Steven C. Johnston
Irina Nikolaevna Kadiyala
Ritu Rohit Kaushik
Ali Keshavarz-Shokri
Mariusz Krawiec
Elaine Chungmin Lee
Brian Luisi
Ales Medek
Praveen Mudunuri
Mehdi Numa
Urvi Jagdishbhai Sheth
Alina Silina
Mark Jeffrey Sullivan
Marinus Jacobus Verwijs
Xiaoqing Yang
Christopher Ryan Young
Noreen Tasneem Zaman
Beili Zhang
Yuegang Zhang
Gregor Zlokarnik
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP11718597A priority Critical patent/EP2560650A1/fr
Priority to AU2011242454A priority patent/AU2011242454A1/en
Priority to CA2796602A priority patent/CA2796602A1/fr
Priority to NZ603043A priority patent/NZ603043A/en
Publication of WO2011133953A1 publication Critical patent/WO2011133953A1/fr
Priority to US13/657,345 priority patent/US20130131107A1/en
Priority to US14/630,778 priority patent/US20160022665A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Definitions

  • the present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV.
  • the invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
  • Cystic fibrosis is a recessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 children and adults in Europe. Despite progress in the treatment of CF, there is no cure.
  • CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes an epithelial chloride ion channel responsible for aiding in the regulation of salt and water absorption and secretion in various tissues.
  • Small molecule drugs known as potentiators that increase the probability of CFTR channel opening, represent one potential therapeutic strategy to treat CF. Potentiators of this type are disclosed in WO 2006/002421, which is herein incorporated by reference in its entirety.
  • Another potential therapeutic strategy involves small molecule drugs known as CF correctors that increase the number and function of CFTR channels. Correctors of this type are disclosed in WO 2005/075435, which are herein incorporated by reference in their entirety.
  • CFTR is a cAMP/ATP-mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins.
  • epithelia cells normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • CFTR cystic fibrosis
  • a defect in this gene causes mutations in CFTR resulting in cystic fibrosis ("CF"), the most common fatal genetic disease in humans. Cystic fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
  • the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as AF508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease.
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + -ATPase pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • CFTR mediated diseases such as Cystic Fibrosis
  • CFTR potentiator compounds such as compounds of Formula I and Formula II
  • combination therapies to treat CFTR mediated diseases, such as Cystic Fibrosis which include CFTR potentiator compounds, such as compounds of Formula I and Formula II in combination with CFTR corrector compounds such as compounds of Formula III and/or Formula IV.
  • compositions comprising:
  • Each of WR and WR is independently selected from CN, CF 3 , halo, C 2-6 straight or branched alkyl, C 3-
  • WR W5 is selected from hydrogen, -OCF 3> -CF 3j -OH, -OCH ⁇ -NH 2 , -CN, -CHF 2 ,
  • Each R' is independently selected from an optionally substituted group selected from a C
  • WR W2 , WR W4 and WR W5 are not -OCH 2 CH 2 Ph, -OCH 2 CH 2 (2-trifluoromethyl-phenyl), - OCH 2 CH 2 -(6,7-dimethoxy-l,2,3,4-tetrahydroisoquinolin-2-yl), or substituted lH-pyrazol-3- yi;
  • ring A is selected from:
  • R 1 is -CF 3 , -CN, or -C ⁇ CCH 2 N(CH 3 ) 2 ;
  • R 2 is hydrogen, -CH 3 , -CF 3 , -OH, or -CH 2 OH;
  • R 3 is hydrogen, -CH 3 , -OCH 3 , or -CN;
  • T is -CH 2 -, -CH 2 CH 2 -, -CF 2 -, -C(CH 3 ) 2 -, or -C(O)-;
  • Ri' is H, Ci-6 aliphatic, halo, CF 3 , CHF 2 , 0(C
  • Z D is a bond, CONH, S0 2 NH, S0 2 N(C,. 6 alkyl), CH 2 NHS0 2 ,
  • R 9 is H, Ci -6 aliphatic, or aryl
  • R is H, OH, OCH 3 or two R taken together form -OCH 2 0- or -OCF 2 0-;
  • R 4 is H or alkyl
  • R 5 is H or F
  • R 6 is H or CN
  • R 7 is H, -CH 2 CH(OH)CH 2 OH, -CH 2 CH 2 N + (CH 3 )3, or -CH 2 CH 2 0H;
  • R 8 is H, OH, -CH 2 CH(OH)CH 2 OH, -CH 2 OH, or R 7 and R 8 taken together form a five membered ring.
  • the pharmaceutical composition comprises a Compound of Formula I and Compound of Formula II.
  • the pharmaceutical composition comprises Compound 1 and Compound 2.
  • the pharmaceutical composition comprises Compound 1, Compound 2 and Compound 3 and/or Compound 4.
  • the pharmaceutical composition comprises Compound 1, Compound 2, and Compound 3.
  • the pharmaceutical composition comprises Compound 1,
  • the pharmaceutical composition comprises Compound 1, Compound 2, Compound 3 and Compound 4.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one component from Column A of Table I, and at least one component from Column B of Table I, and optionally an additional component from one or both of Column C and/or Column D.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one component from Column A of Table I, and optionally an additional component from one or both of Column C and/or Column D.
  • the Column A component is a compound of Formula I
  • the Column B Component is a compound of Formula II
  • the third Component is any of the embodiments listed in Column C.
  • the Column C component is a Compound of Formula III.
  • the Column C component is Compound 3.
  • the Column C component is Compound 3 Form I.
  • the Column C component is
  • the Column C component is Compound 3 HC1 Salt Form A.
  • the Column C component is Compound 3 Form I Aqueous Formulation.
  • the Column C component is Compound 3 Form I Capsule Formulation.
  • the Column C component is Compound 3 Form I Tablet Formulation.
  • the Column A component is a compound of Formula I
  • the Column B Component is a compound of Formula II
  • the third component is a compound of Formula III
  • Component is any of the embodiments listed in Column D.
  • the Column D component is a Compound of Formula IV.
  • the Column D component is Compound 4.
  • the Column D component is Compound 4 Form A.
  • the Column D component is Compound 4 Amorphous Form.
  • the Column D component is Compound 4 Tablet Formulation.
  • the Column A component is a compound of Formula I
  • the Column B Component is a compound of Formula II
  • the third Component is any of the embodiments listed in Column C
  • the fourth component in any of the embodiments listed in Column D.
  • the Column C component is a Compound of Formula III.
  • the Column C component is Compound 3.
  • the Column C component is Compound 3 Form I.
  • the Column C component is Compound 3 Solvate Form A.
  • the Column C component is Compound 3 HC1 Salt Form A.
  • the Column C component is Compound 3 Form I Aqueous Formulation.
  • the Column C component is Compound 3 Form I Capsule Formulation.
  • the Column C component is
  • the Column D component is a Compound of Formula IV.
  • the Column D component is Compound 4.
  • the Column D component is Compound 4 Form A.
  • the Column D component is Compound 4
  • the Column D component is Compound 4 Tablet Formulation.
  • the Column C component is a compound of Formula III, and is in combination with one of any embodiment of Column A and one of any embodiment of Column B.
  • the Column A component is a compound of Formula I.
  • the Column A component is Compound 1.
  • the Column A component is Compound 1 Form C.
  • the Column A component is Compound 1 First Formulation.
  • the Column A component is Compound 1 Tablet and SDD Formulation.
  • the Column B component is a compound of Formula II.
  • the Column B component is Compound 2.
  • the Column B component is Compound 2 Form A.
  • the Column B component is Compound 2 Form A- HC1. In another further embodiment, the Column B component is Compound 2 Form B-HC1. In another further embodiment, the Column B component is Compound 2 Form B. [0032] In one embodiment based on Table I, the Column D component is a compound of Formula IV, and is in combination with one of any embodiment of Column A and one of any embodiment of Column B. In a further embodiment, the Column A component is a compound of Formula I. In another further embodiment, the Column A component is Compound 1. In another further embodiment, the Column A component is Compound 1 Form C. In another further embodiment, the Column A component is Compound 1 First Formulation. In another further embodiment, the Column A component is Compound 1 Tablet and SDD Formulation.
  • the Column B component is a compound of Formula II. In another further embodiment, the Column B component is Compound 2. In another further embodiment, the Column B component is Compound 2 Form A. In another further embodiment, the Column B component is Compound 2 Form A- HC1. In another further embodiment, the Column B component is Compound 2 Form B-HC1. In another further embodiment, the Column B component is Compound 2 Form B.
  • the Column D component is a compound of Formula IV and the Column C component is a compound of Formula III, both of which are in combination with one of any embodiment of Column A and one of any embodiment of Column B.
  • the Column A component is a compound of Formula I.
  • the Column A component is Compound 1.
  • the Column A component is Compound 1 Form C.
  • the Column A component is Compound 1 First Formulation.
  • the Column A component is Compound 1 Tablet and SDD Formulation.
  • the Column B component is a compound of Formula II.
  • the Column B component is Compound 2.
  • the Column B component is Compound 2 Form A.
  • the Column B component is Compound 2 Form A-HC1.
  • the Column B component is Compound 2 Form B-HC1.
  • the Column B component is Compound 2 Form B.
  • the Column B component is Compound 2 Form B.
  • the Column C component is Compound 3, and is in combination with one of any embodiment of Column A and one of any embodiment of Column B.
  • the Column A component is a compound of Formula I.
  • the Column A component is Compound 1.
  • the Column A component is Compound 1 Form C.
  • the Column A component is Compound 1 First Formulation.
  • the Column A component is Compound 1 Tablet and SDD Formulation.
  • the Column B component is a compound of Formula II.
  • the Column B component is Compound 2.
  • the Column B component is Compound 2 Form A.
  • the Column B component is Compound 2 Form A-HC1.
  • the Column B component is Compound 2 Form B-HC1.
  • the Column B component is Compound 2 Form B.
  • the Column B component is Compound 2 Form B.
  • the Column D component is Compound 4, and is in combination with one of any embodiment of Column A and one of any embodiment of Column B.
  • the Column A component is a compound of Formula I.
  • the Column A component is Compound 1.
  • the Column A component is Compound 1 Form C.
  • the Column A component is Compound 1 First Formulation.
  • the Column A component is Compound 1 Tablet and SDD Formulation.
  • the Column B component is a compound of Formula II.
  • the Column B component is Compound 2.
  • the Column B component is Compound 2 Form A.
  • the Column B component is Compound 2 Form A-HC1.
  • the Column B component is Compound 2 Form B-HC1.
  • the Column B component is Compound 2 Form B.
  • the Column B component is Compound 2 Form B.
  • the Column D component is Compound 4 and the Column C component is Compound 3, both of which are in combination with one of any embodiment of Column A and one of any embodiment of Column B.
  • the Column A component is a compound of Formula I. In another further embodiment, the Column A component is Compound 1. In another further embodiment, the Column A component is Compound 1 Form C. In another further embodiment, the Column A component is Compound 1 First Formulation. In another further embodiment, the Column A component is Compound 1 Tablet and SDD Formulation. In a further embodiment, the Column B component is a compound of Formula II. In another further embodiment, the Column B component is Compound 2. In another further embodiment, the Column B component is Compound 2 Form A. In another further embodiment, the Column B component is Compound 2 Form A-HC1. In another further embodiment, the Column B component is Compound 2 Form B-HC1. In another further embodiment, the Column B component is Compound 2 Form B.
  • the Column A component is Compound 1
  • the Column B Component is Compound 2
  • the third Component is any of the embodiments listed in Column C.
  • the Column C component is a Compound of Formula III.
  • the Column C component is Compound 3.
  • the Column C component is Compound 3 Form I.
  • the Column C component is Compound 3 Solvate Form A.
  • the Column C component is Compound 3 HC1 Salt Form A.
  • the Column C component is Compound 3 Form I Aqueous Formulation.
  • the Column C component is Compound 3 Form I Capsule Formulation.
  • the Column C component is Compound 3 Form I Tablet Formulation.
  • the Column A component is Compound 1
  • the Column B Component is Compound 2
  • the third Component is any of the
  • the Column D component is a Compound of Formula IV. In another further embodiment, the Column D component is Compound 4. In another further embodiment, the Column D component is Compound 4 Form A. In another further embodiment, the Column D component is Compound 4
  • the Column D component is Compound 4 Tablet Formulation.
  • the Column A component is Compound 1
  • the Column B Component is Compound 2
  • the third Component is any of the embodiments listed in Column C
  • the fourth component is any of the embodiments listed in Column D.
  • the Column C component is a Compound of Formula III.
  • the Column C component is Compound 3.
  • the Column C component is Compound 3 Form I.
  • the Column C component is Compound 3 Solvate Form A.
  • the Column C component is Compound 3 HC1 Salt Form A.
  • the Column C component is Compound 3 Form I Aqueous Formulation.
  • the Column C component is Compound 3 Form I Capsule Formulation.
  • the Column C component is Compound 3 Form I Tablet Formulation.
  • the Column D component is a Compound of Formula IV.
  • the Column D component is Compound 4.
  • the Column D component is Compound 4 Form A.
  • the Column D component is Compound 4 Amorphous Form.
  • the Column D component is Compound 4 Tablet Formulation.
  • the Column A component is Compound 1
  • the Column A component is Compound 1
  • the Column B Component is Compound 2
  • the third Component is Compound 4.
  • the Column A component is Compound 1
  • the invention is directed to method of treating a CFTR mediated disease in a human comprising administering to the human an effective amount of a pharmaceutical composition comprising a pharmaceutical composition according to Table I.
  • the invention is directed to method of treating a CFTR mediated disease in a human comprising administering to the human an effective amount of a pharmaceutical composition comprising Compound 1 and Compound 2, according to Table I.
  • the invention is directed to a kit comprising a pharmaceutical composition comprising a compound of Formula I and Formula II, according to Table I.
  • the invention is directed to a kit comprising a pharmaceutical composition comprising a compound of Compound 1 and Compound 2, according to Table I.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one component from Column A of Table I, and optionally an additional component from one or both of Column C and/or Column D.
  • the Column A component is a compound of Formula I. In another embodiment, the Column A component is Compound 1. In another embodiment, the Column A component is Compound 1 Form C. In another embodiment, the Column A component is Compound 1 First Formulation. In still another embodiment, the Column A component is Compound I SDD and Tablet Formulation.
  • the Column C component is a Compound of Formula III. In a further embodiment, the Column C component is Compound 3. In another further embodiment, the Column C component is Compound 3 Form I. In another further embodiment, the Column C component is Compound 3 Solvate Form A. In another further embodiment, the Column C component is Compound 3 HC1 Salt Form A. In another further embodiment, the Column C component is Compound 3 Form I Aqueous Formulation. In another further embodiment, the Column C component is Compound 3 Form I Capsule Formulation. In still another further embodiment, the Column C component is Compound 3 Form I Tablet Formulation.
  • the Column D component is a Compound of Formula IV. In another further embodiment, the Column D component is Compound 4. In another further embodiment, the Column D component is Compound 4 Form A. In another further embodiment, the Column D component is Compound 4 Amorphous Form. In still another further embodiment, the Column D component is Compound 4 Tablet Formulation.
  • the Column A component is Compound 1 Tablet and SDD formulation, which is in combination with Compound 3 Tablet Formulation or Compound 3 Capsule Formulation.
  • the Column A component is Compound 1 Tablet and SDD formulation, which is in combination with Compound 4 Tablet Formulation.
  • the Column A component is Compound 1 Tablet and SDD Formulation, which is combination with Compound 3 Tablet Formulation or Compound 3 Capsule Formulation, and in combination with Compound 4 Tablet Formulation.
  • Figure 1-1 is an X-Ray powder diffraction pattern of Form C of Compound 1.
  • Figure 1-2 is a DSC trace of Compound 1 Form C.
  • Figure 1-3 is a TGA trace of Compound 1 Form C.
  • Figure 1-4 is a Raman spectrum of Compound 1 Form C.
  • Figure 1-5 is an FTIR spectrum of Compound 1 Form C.
  • Figure 1-6 is a Solid State NMR Spectrum of Compound 1 Form C.
  • Figure 2-1 is an X-Ray powder diffraction pattern of Compound 2 Form A.
  • Figure 2-2 is an X-Ray Crystal Structure of Compound 2 Form A.
  • Figure 2-3 is an FTIR Spectrum of Compound 2 Form A.
  • Figure 2-4 is an XRPD Structure of Compound 2 Form A-HC1.
  • Figure 2-5 is a l3 C NMR Spectrum of Compound 2 Form A-HCl.
  • Figure 2-6 is a l9 F NMR Spectrum of Compound 2 Form A-HCl.
  • Figure 2-7 is an FTIR Spectrum of Compound 2 Form A-HCl.
  • Figure 2-8 is a DSC Curve of Compound 2 Form A-HCl.
  • Figure 2-9 is a TGA trace of Compound 2 Form A-HCl.
  • Figure 2-10 is an XRPD Pattern of Compound 2 Form B-HCl.
  • Figure 2-11 is an FTIR Spectrum of Compound 2 Form B-HCl.
  • Figure 2-12 is a DSC Curve of Compound 2 Form B-HCl.
  • Figure 2-13 is a TGA trace of Compound 2 Form B-HCl.
  • Figure 2-14 is a 13 C SSNMR Spectrum of Compound 2 Form B-HCl.
  • Figure 2-15 is a 19 F SSNMR Spectrum of Compound 2 Form B-HCl.
  • Figure 2- 16 A is an XRPD Pattern for a representative sample of Compound 2
  • Figure 2-16B is an XRPD Pattern for a representative sample of Compound 2 Form B recorded with Instrument 2.
  • Figure 2-17 is an FTIR Spectrum of Compound 2 Form B .
  • Figure 2-18 is a 13 C SSNMR Spectrum of Compound 2 Form B.
  • Figure 2-19 is a l9 F SSNMR Spectrum of Compound 2 Form B.
  • Figure 2-20 is a DSC Curve of Compound 2 Form B .
  • Figure 2-21 is a TGA of Compound 2 Form B .
  • Figure 2-22 is an illustration of the conformational structure of Compound 2 Form B based on single crystal X-ray analysis.
  • Figure 2-23 is an illustration of the conformational structure of Compound 2 Form A-HCl based on X-ray analysis.
  • Figure 2-24 is a molecular packing diagram of Compound 2 Form A-HCl based on X-ray analysis.
  • Figure 2-25 is an illustration of the conformational structure of Compound 2 Form B-HCl based on X-ray analysis.
  • Figure 2-26 is a molecular packing diagram of Compound 2 Form B-HCl based on single X-ray analysis.
  • Figure 3-1 is an X-ray diffraction pattern calculated from a single crystal structure of Compound 3 Form I.
  • Figure 3-2 is an actual X-ray powder diffraction pattern of Compound 3 Form I.
  • Figure 3-3 is a conformational picture of Compound 3 Form I based on single crystal X-ray analysis.
  • Figure 3-4 is an X-ray powder diffraction pattern of Compound 3 Solvate Form A.
  • Figure 3-5 is a Stacked, multi-pattern spectrum of the X-ray diffraction patterns of Compound 3 Solvate Forms selected from:
  • Figure 3-6 is an X-ray diffraction pattern of Compound 3, Methanol Solvate Form A.
  • Figure 3-7 is an X-ray diffraction pattern of Compound 3, Ethanol Solvate Form A.
  • Figure 3-8 is an X-ray diffraction pattern of Compound 3 Acetone Solvate Form A.
  • Figure 3-9 is an X-ray diffraction pattern of Compound 3, 2-Propanol Solvate Form A.
  • Figure 3-10 is an X-ray diffraction pattern of Compound 3, Acetonitrile Solvate Form A.
  • Figure 3-11 is an X-ray diffraction pattern of Compound 3, Tetrahydrofuran Solvate Form A.
  • Figure 3-12 is an X-ray diffraction pattern of Compound 3, Methyl Acetate Solvate Form A.
  • Figure 3-13 is an X-ray diffraction pattern of Compound 3, 2-Butanone Solvate Form A.
  • Figure 3-14 is an X-ray diffraction pattern of Compound 3, Ethyl Formate Solvate Form A.
  • Figure 3-15 is an X-ray diffraction pattern of Compound 3, 2- Methyltetrahydrofuran Solvate Form A.
  • Figure 3-16 is a conformational image of Compound 3 Acetone Solvate Form A based on single crystal X-ray analysis.
  • Figure 3-17 is a conformational image of Compound 3 Solvate Form A based on single crystal X-ray analysis as a dimer.
  • Figure 3-18 is a conformational image of Compound 3 Solvate Form A showing hydrogen bonding between carboxylic acid groups based on single crystal X-ray analysis.
  • Figure 3-19 is a conformational image of Compound 3 Solvate Form A showing acetone as the solvate based on single crystal X-ray analysis.
  • Figure 3-20 is a conformational image of the dimer of Compound 3 HC1 Salt Form A.
  • Figure 3-21 is a packing diagram of Compound 3 HC1 Salt Form A.
  • Figure 3-22 is an X-ray diffraction pattern of Compound 3 HC1 Salt Form A calculated from the crystal structure.
  • Figure 3-23 is an overlay of X-ray powder diffraction patterns of Compound 3 HC1 salt and the same compound after being suspended in an aqueous methylcellulose formulation for 24 hours at room temperature.
  • Figure 3-24 is an 'HNMR analysis of Compound 3 from a 50mg/mL
  • Figure 3-25 is an 'HNMR analysis of Compound 3 from a 50mg/mL
  • Figure 3-26 is an 'HNMR analysis of Compound 3 HC1 salt standard.
  • Figure 3-27 is a 13 C SSNMR Spectrum of Compound 3 Form I.
  • Figure 3-28 is a 19 F SSNMR Spectrum of Compound 3 Form I (15.0 kHz Spinning).
  • Figure 3-29 is a l3 C SSNMR Spectrum of Compound 3 Acetone Solvate Form A.
  • Figure 3-30 is a 19 F SSNMR Spectrum of Compound 3 Acetone Solvate Form A (15.0 kHz Spinning).
  • Figure 4-1 is an X-ray powder diffraction pattern calculated from a single crystal of Compound 4 Form A.
  • Figure 4-2 is an actual X-ray powder diffraction pattern of Compound 4 Form A prepared by the slurry technique (2 weeks) with DCM as the solvent.
  • Figure 4-3 is an actual X-ray powder diffraction pattern of Compound 4 Form A prepared by the fast evaporation method from acetonitrile.
  • Figure 4-4 is an actual X-ray powder diffraction pattern of Compound 4 Form A prepared by the anti solvent method using EtOAc and heptane.
  • Figure 4-5 is a conformational picture of Compound 4 Form A based on single crystal X-ray analysis.
  • Figure 4-6 is a conformational picture showing the stacking order of Compound 4 Form A.
  • Figure 4-7 is a 13 C SSNMR spectrum (15.0 kHz spinning) of Compound 4 Form A.
  • Figure 4-8 is a 19 F SSNMR spectrum (12.5 kHz spinning) of Compound 4 Form A.
  • Figure 4-9 is an X-ray powder diffraction pattern of Compound 4 amorphous form from the fast evaporation rotary evaporation method.
  • Figure 4-10 is an X-ray powder diffraction pattern of Compound 4 amorphous form prepared by spray dried methods.
  • Figure 4-11 is a solid state 13 C NMR spectrum (15.0 kHz spinning) of Compound 4 amorphous form.
  • Figure 4-12 is a solid state l9 F NMR spectrum ( 12.5 kHz spinning) of Compound 4 amorphous form.
  • ABS-transporter as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro.
  • binding domain as used herein means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et al, J. Gen. Physiol. (1998): 777(3), 477-90.
  • CFTR cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, AF508 CFTR, Rl 17H CFTR, and G551D CFTR (see, e.g.,
  • API active pharmaceutical ingredient
  • CF potentiators N-[2,4-bis(l,l- dimethylethyl)-5-hydroxyphenyl]- 1 ,4-dihydro-4-oxoquinoline-3 -carboxamide
  • Representative APIs include the CF potentiators N-[2,4-bis(l,l- dimethylethyl)-5-hydroxyphenyl]- 1 ,4-dihydro-4-oxoquinoline-3 -carboxamide (Compound 1 ) and N-(4-(7-azabicyclo[2.2.1 ]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5- (trifluoromethyl)-l,4-dihydroquinoline-3-carboxamide (Compound 2).
  • Exemplary APIs also include the CF correctors 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 3) and (R)-l- (2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2- methylpropan-2-yl)- 1 H-indol-5-yl)cyclopropanecarboxamide (Compound 4).
  • modulating means increasing or decreasing by a measurable amount.
  • normal CFTR or "normal CFTR function” as used herein means wild-type like CFTR without any impairment due to environmental factors such as smoking, pollution, or anything that produces inflammation in the lungs.
  • reduced CFTR or "reduced CFTR function” as used herein means less than normal CFTR or less than normal CFTR function.
  • amorphous refers to a solid material having no long range order in the position of its molecules.
  • Amorphous solids are generally supercooled liquids in which the molecules are arranged in a random manner so that there is no well- defined arrangement, e.g., molecular packing, and no long range order.
  • Amorphous solids are generally isotropic, i.e. exhibit similar properties in all directions and do not have definite melting points.
  • an amorphous material is a solid material having no sharp characteristic crystalline peak(s) in its X-ray power diffraction (XRPD) pattern (i.e., is not crystalline as determined by XRPD). Instead, one or several broad peaks (e.g., halos) appear in its XRPD pattern. Broad peaks are characteristic of an amorphous solid. See, US
  • substantially amorphous refers to a solid material having little or no long range order in the position of its molecules.
  • substantially amorphous materials have less than about 15% crystallinity (e.g., less than about 10% crystallinity or less than about 5% crystallinity). It is also noted that the term 'substantially amorphous' includes the descriptor, 'amorphous', which refers to materials having no (0%) crystallinity.
  • the term "dispersion” refers to a disperse system in which one substance, the dispersed phase, is distributed, in discrete units, throughout a second substance (the continuous phase or vehicle).
  • the size of the dispersed phase can vary considerably (e.g. single molecules, colloidal particles of nanometer dimension, to multiple microns in size).
  • the dispersed phases can be solids, liquids, or gases. In the case of a solid dispersion, the dispersed and continuous phases are both solids.
  • a solid dispersion can include: an amorphous drug in an amorphous polymer; an amorphous drug in crystalline polymer; a crystalline drug in an amorphous polymer; or a crystalline drug in crystalline polymer.
  • a solid dispersion can include an amorphous drug in an amorphous polymer or an amorphous drug in crystalline polymer.
  • a solid dispersion includes the polymer constituting the dispersed phase, and the drug constitutes the continuous phase.
  • a solid dispersion includes the drug constituting the dispersed phase, and the polymer constitutes the continuous phase.
  • solid dispersion generally refers to a solid dispersion of two or more components, usually one or more drugs (e.g., one drug (e.g., Compound 1)) and polymer, but possibly containing other components such as surfactants or other pharmaceutical excipients, where the drug(s) (e.g., Compound 1) is substantially amorphous (e.g., having about 15% or less (e.g., about 10% or less, or about 5% or less)) of crystalline drug (e.g., N-[2,4-bis(l,l-dimethylethyl)-5-hydroxyphenyl]-l,4-dihydro-4- oxoquinoline-3-carboxamide) or amorphous (i.e., having no crystalline drug), and the physical stability and/or dissolution and/or solubility of the substantially amorphous or amorphous drug is enhanced by the other components.
  • drugs e.g., one drug (e.g., Compound 1)
  • polymer but
  • Solid dispersions typically include a compound dispersed in an appropriate carrier medium, such as a solid state carrier.
  • a carrier comprises a polymer (e.g., a water-soluble polymer or a partially water- soluble polymer) and can include optional excipients such as functional excipients (e.g., one or more surfactants) or nonfunctional excipients (e.g., one or more fillers).
  • Another exemplary solid dispersion is a co-precipitate or a co-melt of N-[2,4-bis(l,l-dimethylethyl)- 5-hydroxyphenyl]-l,4-dihydro-4-oxoquinoline-3-carboxamide with at least one polymer.
  • a "Co-precipitate” is a product after dissolving a drug and a polymer in a solvent or solvent mixture followed by the removal of the solvent or solvent mixture.
  • the polymer can be suspended in the solvent or solvent mixture.
  • the solvent or solvent mixture includes organic solvents and supercritical fluids.
  • a "co-melt" is a product after heating a drug and a polymer to melt, optionally in the presence of a solvent or solvent mixture, followed by mixing, removal of at least a portion of the solvent if applicable, and cooling to room temperature at a selected rate.
  • crystalline refers to compounds or compositions where the structural units are arranged in fixed geometric patterns or lattices, so that crystalline solids have rigid long range order.
  • the structural units that constitute the crystal structure can be atoms, molecules, or ions. Crystalline solids show definite melting points.
  • substantially crystalline means a solid material that is arranged in fixed geometric patterns or lattices that have rigid long range order.
  • substantially crystalline materials have more than about 85% crystallinity (e.g., more than about 90% crystallinity or more than about 95% crystallinity).
  • the term 'substantially crystalline' includes the descriptor 'crystalline', which is defined in the previous paragraph.
  • crystallinity refers to the degree of structural order in a solid.
  • Compound 1, which is substantially amorphous has less than about 15% crystallinity, or its solid state structure is less than about 15% crystalline.
  • Compound 1, which is amorphous has zero (0%) crystallinity.
  • excipient is an inactive ingredient in a pharmaceutical composition.
  • excipients include fillers or diluents, surfactants, binders, glidants, lubricants, disintegrants, and the like.
  • a "disintegrant” is an excipient that hydrates a pharmaceutical composition and aids in tablet dispersion.
  • disintegrants include sodium croscarmellose and/or sodium starch glycolate.
  • a "diluent” or “filler” is an excipient that adds bulkiness to a pharmaceutical composition.
  • fillers include lactose, sorbitol, celluloses, calcium phosphates, starches, sugars (e.g., mannitol, sucrose, or the like) or any combination thereof.
  • a "surfactant” is an excipient that imparts pharmaceutical compositions with enhanced solubility and/or wetability.
  • surfactants include sodium lauryl sulfate (SLS), sodium stearyl fumarate (SSF), polyoxyethylene 20 sorbitan mono-oleate (e.g., TweenTM), or any combination thereof.
  • a "binder” is an excipient that imparts a pharmaceutical composition with enhanced cohesion or tensile strength (e.g., hardness).
  • binders include dibasic calcium phosphate, sucrose, corn (maize) starch, microcrystalline cellulose, and modified cellulose (e.g., hydroxymethyl cellulose).
  • a "glidant” is an excipient that imparts a pharmaceutical compositions with enhanced flow properties. Examples of glidants include colloidal silica and/or talc.
  • a "colorant” is an excipient that imparts a pharmaceutical composition with a desired color.
  • examples of colorants include commercially available pigments such as FD&C Blue # 1 Aluminum Lake, FD&C Blue #2, other FD&C Blue colors, titanium dioxide, iron oxide, and/or combinations thereof.
  • a "lubricant” is an excipient that is added to pharmaceutical compositions that are pressed into tablets.
  • the lubricant aids in compaction of granules into tablets and ejection of a tablet of a pharmaceutical composition from a die press.
  • examples of lubricants include magnesium stearate, stearic acid (stearin), hydrogenated oil, sodium stearyl fumarate, or any combination thereof.
  • Friability refers to the property of a tablet to remain intact and withhold its form despite an external force of pressure. Friability can be quantified using the mathematical expression presented in equation 1 :
  • %friabiliy ⁇ Wx— ⁇ (1) wherein Wo is the original weight of the tablet and Wf is the final weight of the tablet after it is put through the friabilator.
  • Friability is measured using a standard USP testing apparatus that tumbles experimental tablets for 100 revolutions. Some tablets of the present invention have a friability of less than about 1% (e.g., less than about 0.75%, less than about 0.50%, or less than about 0.30%)
  • mean particle diameter is the average particle diameter as measured using techniques such as laser light scattering, image analysis, or sieve analysis.
  • bulk density is the mass of particles of material divided by the total volume the particles occupy. The total volume includes particle volume, inter- particle void volume and internal pore volume. Bulk density is not an intrinsic property of a material; it can change depending on how the material is processed.
  • aliphatic or "aliphatic group,” as used herein, means a straight- chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” "cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other
  • aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms.
  • cycloaliphatic (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C8 hydrocarbon or bicyclic or tricyclic C 8 -Ci 4 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • Suitable cycloaliphatic groups include cycloalkyl, bicyclic cycloalkyl (e.g., decalin), bridged bicycloalkyl such as norbornyl or [2.2.2]bicyclo-octyl, or bridged tricyclic such as adamantyl.
  • alkyl refers to a saturated aliphatic hydrocarbon group containing 1-15 (including, but not limited to, 1-8, 1-6, 1-4, 2-6, 3-12) carbon atoms.
  • An alkyl group can be straight or branched.
  • heteroaliphatic means aliphatic groups wherein one or two carbon atoms are independently replaced by one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon. Heteroaliphatic groups may be substituted or unsubstituted, branched or unbranched, cyclic or acyclic, and include "heterocycle,” “heterocyclyl,” “heterocycloaliphatic,” or “heterocyclic” groups.
  • heterocycle means “heterocycle,” “heterocyclyl,” “heterocycloaliphatic,” or
  • heterocyclic as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom.
  • heterocycle means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom.
  • heterocyclyl means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom.
  • heterocycloaliphatic or
  • heterocyclic group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring.”
  • aryl also refers to heteroaryl ring systems as defined herein below.
  • Optional substituents on the aliphatic group of R * are selected from NH 2 , NH(C
  • Optional substituents on the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(C
  • two independent occurrences of R are taken together with the atom(s) to which each variable is bound to form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Exemplary rings that are formed when two independent occurrences of R (or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R (or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R ) 2 , where both occurrences of R' are taken together with the nitrogen atom to form a piperidin-l-yl, piperazin-l-yl, or morpholin- 4-yl group; and b) two independent occurrences of R (or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for example where a phenyl group is substituted with two occurrences of OR these two occurrences of R° are taken together with the oxygen atoms to
  • a substituent bond in, e.g., a bicyclic ring system, as shown below, means that the substituent can be attached to any substitutable ring atom on either ring of the bicyclic ring system:
  • protecting group represents those groups intended to protect a functional group, such as, for example, an alcohol, amine, carboxyl, carbonyl, etc., against undesirable reactions during synthetic procedures. Commonly used protecting groups are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, 3 rd Edition (John Wiley & Sons, New York, 1 99), which is incorporated herein by reference.
  • nitrogen protecting groups include acyl, aroyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl,
  • trichloroacetyl phthalyl, o-nitrophenoxyacetyl, cc-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4- bromobenzoyl, 4-nitrobenzoyl and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, phenylalanine and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; carbamate groups such as
  • benzyloxycarbonyl p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p- nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4- dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4- dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5- dimethoxybenzyloxycarbonyl , 3 ,4,5-trimetho ybenzyloxycarbonyl , 1 -(p-biphenylyl)- 1 - methylethoxycarbonyl, a,a-dimethyl-3,5-dimethoxybenzyIoxycarbonyl,
  • N-protecting groups are tert-butyloxycarbonyl (Boc).
  • Examples of useful protecting groups for acids are substituted alkyl esters such as 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl,
  • Preferred protecting groups for acids are methyl or ethyl esters.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • Suitable solvents are, but not limited to, water, methanol,
  • dichloromethane DCM
  • acetonitrile dimethylformamide
  • EtOAc ethyl acetate
  • EPA isopropyl alcohol
  • IP Ac isopropyl acetate
  • THF tetrahydrofuran
  • MEK methyl ethyl ketone
  • NMP N-methyl pyrrolidone
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I and a Compound of Formula II, optionally in combination with one or both of a Compound of Formula III and/or a Compound of Formula IV.
  • the invention includes a composition comprising a compound of Formula I
  • Each of WR W2 and WR W4 is independently selected from CN, CF 3 , halo, C 2- 6 straight or branched alkyl, C 3- i 2 membered cycloaliphatic, phenyl, a 5-10 membered heteroaryl or 3-7 membered heterocyclic, wherein said heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WR W2 and WR W4 is independently and optionally substituted with up to three substituents selected from -OR', -CF 3 , -OCF 3 , SR', S(0)R ⁇ S0 2 R ⁇ -SCF 3 , halo, CN, -COOR', -COR', -0(CH 2 ) 2 N(R') 2 , -0(CH 2 )N(R') 2 , -CON(R') 2 , - (CH 2 ) 2 OR', -(CH 2 )OR',
  • WR W5 is selected from hydrogen, -OCF 3> -CF 3> -OH, -OCH 3j -NH 2 , -CN, -CHF 2 ,
  • Each R' is independently selected from an optionally substituted group selected from a Ci-8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • WR W2 , WR W4 and WR W5 are not -OCH 2 CH 2 Ph, -OCH 2 CH 2 (2-trifluoromethyl-phenyl), - OCH 2 CH 2 -(6,7-dimethoxy-l,2,3,4-tetrahydroisoquinolin-2-yl), or substituted lH-pyrazol-3- yi-
  • each of WR W2 and WR W4 is independently selected from CN, CF 3 , halo, C 2-6 straight or branched alkyl, C 3- i 2 membered cycloaliphatic, or phenyl, wherein said WR W2 and WR W4 is independently and optionally substituted with up to three substituents selected from -OR', -CF 3 , -OCF3, -SCF 3 , halo, -COOR', -COR', -0(CH 2 ) 2 N(R') 2 , -0(CH 2 )N(R') 2 , -CON(R') 2 , -(CH 2 ) 2 OR ⁇ -(CH 2 )OR ⁇ optionally substituted phenyl, -N(R') 2 , -NC(0)OR ⁇ -NC(0)R ⁇ -(CH 2 ) 2 N(R') 2 , or
  • each of WR W2 and WR W4 is independently selected from -CN, - CF 3 , C 2 -6 straight or branched alkyl, C3-i 2 membered cycloaliphatic, or phenyl, wherein each of said WR W2 and WR W4 is independently and optionally substituted with up to three substituents selected from -OR', -CF 3 , -OCF 3 , -SCF 3 , halo, -COOR', -COR',
  • WR W5 is selected from -OH, -CN, -NHR', -N(R') 2 , -NHC(0)R', -NHC(0)OR', -NHS0 2 R', -CH 2 OH, -C(0)OR', -S0 2 NHR', or -CH 2 NHC(0)0-(R').
  • WR is a phenyl ring optionally substituted with up to three substituents selected from -OR', -CF 3 , -OCF 3 , -SR ⁇ -S(0)R', -S0 2 R', -SCF 3 , halo, -CN, -COOR', -COR', -0(CH 2 ) 2 N(R') 2 , -0(CH 2 )N(R') 2 , -CON(R') 2 , -(CH 2 ) 2 OR',
  • WR W4 is C 2 . 6 straight or branched alkyl
  • WR W5 is -OH.
  • each of WR W2 and WR W4 is independently -CF 3 , -CN, or a C 2- 6 straight or branched alkyl.
  • each of WR W2 and WR W4 is C 2- 6 straight or branched alkyl optionally substituted with up to three substituents independently selected from -OR', -CF 3 , -OCF 3 , -SR', -S(0)R', -S0 2 R', -SCF 3 , halo, -CN, -COOR', -COR', -0(CH 2 ) 2 N(R') 2 , -0(CH 2 )N(R') 2 , -CON(R') 2 , -(CH 2 ) 2 OR ⁇ -(CH 2 )OR', -CH 2 CN, optionally substituted phenyl or phenoxy, -N(R') 2 , -NR'C(0)OR', -NR'C(0)R', -(CH 2 ) 2 N(R') 2 , or -(CH 2 )N(R') 2 .
  • each of WR W2 and WR W4 is independently selected from optionally substituted n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, l,l-dimethyl-2- hydroxyethyl, 1 , 1 -dimethyl-2-(ethoxycarbonyl)-ethyl, 1 , 1 -dimethyl-3-(t-butoxycarbonyl- amino) propyl, or n-pentyl.
  • WR W5 is selected from -CN, -NHR' , -N(R') 2 ,
  • WR W5 is selected from -CN, -NH(Ci -6 alkyl), -N(C
  • WR W5 is selected from -OH, -CH 2 OH,
  • WR is C 2 -6 straight or branched alkyl
  • WR W4 is C 2- 6 straight or branched alkyl or monocyclic or bicyclic
  • WR W5 is selected from -CN, -NH(C l-6 alkyl), -N(C 1-6 alkyl) 2 , -NHC(0)( C, -6 alkyl), -NHC(0)0(C, -6 alkyl), -CH 2 C(0)0(Ci -6 alkyl), -OH, -0(C, -6 alkyl),
  • WR W2 is C 2- 6 alkyl, -CF3, -CN, or phenyl optionally substituted with up to 3 substituents selected from C alkyl, -0(Cu alkyl), or halo;
  • WR W4 is -CF3, C 2 .6 alkyl, or C 6- io cycloaliphatic;
  • WR W5 is -OH, -NH(C 1-6 alkyl), or -N(Ci -6 alkyl) 2 .
  • WR W2 is tert-butyl.
  • WR W4 is iert-butyl.
  • WR W5 is -OH.
  • the compound of Formula I is Compound 1.
  • Compound 1 is known by the name N-[2,4-bis(l,l-dimethylethyl)-5- hydroxyphenyl]-l,4-dihydro-4-oxoquinoline-3-carboxamide and by the name N-(5-hydroxy- 2,4-di-teri-butyl-phenyl)-4-oxo- 1 H-quinoline-3-carboxamide.
  • II.A.3. Synthesis of the Compounds of Formula I
  • WR W2 , W W4 , and WR W5 are as defined previously.
  • EtOCH C(COOEt) 2 to aniline, followed by thermal rearrangement and hydrolysis.
  • Example la Ethyl 4-oxo-l,4-dihydroquinoline-3-carboxylate (25).
  • Example lb 4-Oxo-l,4-dihydroquinoline-3-carboxylic acid (26).
  • Compound 25 (1.0 eq) was suspended in a solution of HCI (10.0 eq) and H 2 0 (11.6 vol). The slurry was heated to 85 - 90 °C, although alternative temperatures are also suitable for this hydrolysis step.
  • the hydrolysis can alternatively be performed at a temperature of from about 75 to about 100 °C. In some instances, the hydrolysis is performed at a temperature of from about 80 to about 95 °C. In others, the hydrolysis step is performed at a temperature of from about 82 to about 93 °C (e.g., from about 82.5 to about 92.5 °C or from about 86 to about 89 °C).
  • the reaction mixture was then slowly heated to 23 - 28 °C and stirred for 20 hours.
  • the reaction was then cooled to 10 - 15 °C and charged with 150 mL water.
  • the mixture was stirred at 15 - 20 °C for 35 - 45 minutes and the aqueous layer was then separated and extracted with 150 mL methylene chloride.
  • the organic layers were combined and neutralized with 2.5% HC1 (aq) at a temperature of 5 - 20 °C to give a final pH of 5 - 6.
  • the organic layer was then washed with water and
  • Example Id 5-Nitro-2,4-di-tert-butyIphenyl methyl carbonate (31).
  • Example le 5-Amino-2,4-di-tert-butylphenyl methyl carbonate (32).
  • the resulting mixture was diluted with from about 5 to 10 volumes of MeOH (e.g., from about 6 to about 9 volumes of MeOH, from about 7 to about 8.5 volumes of MeOH, from about 7.5 to about 8 volumes of MeOH, or about 7.7 volumes of MeOH), heated to a temperature of about 35 ⁇ 5 °C, and filtered to remove palladium.
  • MeOH e.g., from about 6 to about 9 volumes of MeOH, from about 7 to about 8.5 volumes of MeOH, from about 7.5 to about 8 volumes of MeOH, or about 7.7 volumes of MeOH
  • the reactor cake was washed before combining the filtrate and wash, distilling, adding water, cooling, filtering, washing and drying the product cake as described above.
  • the filtered solution was concentrated at no more than 45 °C (jacket temperature) and no less than 8.0 °C (internal reaction temperature) under reduced pressure to 20 vol.
  • CH 3 CN was added to 40 vol and the solution concentrated at no more than 45 °C (jacket temperature) and no less than 8.0 °C (internal reaction temperature) to 20 vol.
  • the addition of CH 3 CN and concentration cycle was repeated 2 more times for a total of 3 additions of CH 3 CN and 4 concentrations to 20 vol. After the final concentration to 20 vol, 16.0 vol of C3 ⁇ 4CN was added followed by 4.0 vol of H 2 0 to make a final concentration of 40 vol of 10%
  • Example lg N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-l,4- dihydroquinoline-3-carboxamide (1).
  • 4-Oxo-l,4-dihydroquinoline-3-carboxylic acid 26 (1.0 eq) and 5-amino-2,4-di-tert-butylphenyl methyl carbonate 32 (1.1 eq) were charged to a reactor.
  • 2-MeTHF (4.0 vol, relative to the acid) was added followed by T3P ® 50% solution in 2-MeTHF (1.7 eq).
  • the T3P charged vessel was washed with 2-MeTHF (0.6 vol).
  • the filtered solution was concentrated at no more than 45 °C (jacket temperature) and no less than 8.0 °C (internal reaction temperature) under reduced pressure to 20 vol.
  • CH3CN was added to 40 vol and the solution concentrated at no more than 45 °C (jacket temperature) and no less than 8.0 °C (internal reaction temperature) to 20 vol.
  • the addition of CH3CN and concentration cycle was repeated 2 more times for a total of 3 additions of CH3CN and 4 concentrations to 20 vol. After the final concentration to 20 vol, 16.0 vol of CH 3 CN was charged followed by 4.0 vol of 3 ⁇ 40 to make a final concentration of 40 vol of 10% H 2 O/CH3CN relative to the starting acid.
  • This slurry was heated to 78.0 °C +/- 5.0 °C (reflux). The slurry was then stirred for no less than 5 hours. The slurry was cooled to 20 to 25 °C over 5 hours, and filtered. The cake was washed with CH 3 CN (5 vol) heated to 20 to 25 °C 4 times. The resulting solid (Compound 1) was dried in a vacuum oven at no more than 50.0 °C.
  • the invention includes a pharmaceutical composition comprising a compound of Formula II
  • ring A is selected from:
  • R 1 is -CF 3 , -CN, or -C ⁇ CCH 2 N(CH 3 ) 2 ;
  • R 2 is hydrogen, -CH 3 , -CF 3 , -OH, or -CH 2 OH;
  • R 3 is hydrogen, -CH 3 , -OCH 3 , or -CN;
  • ring A of Formula II is
  • ring A of Formula II is
  • ring A of Formula II is
  • ring A of Formula II is
  • R 1 of Formula II is -CF 3 .
  • R 1 of Formula II is -CN.
  • R 1 of Formula II is -C ⁇ CCH 2 N(CH 3 ) 2 .
  • R 2 of Formula II is -CH 3 .
  • R 2 of Formula II is -CF 3 .
  • R 2 of Formula II is -OH.
  • R 2 of Formula II is -CH 2 OH.
  • R 3 of Formula II is -CH 3 .
  • R 3 of Formula II is -OCH 3 .
  • R 3 of Formula II is -CN.
  • R 2 of Formula II is hydrogen; and R 3 of Formula II is - CH 3 , -OCH 3 , or -CN.
  • R 2 of Formula II is -CH 3 , -CF 3 , -OH, or -CH 2 OH; and R 3 of Formula II is hydrogen.
  • ring A of Formula II is , R 1 is -CF 3 , R 2 is hydrogen; and R 3 is -CH 3 , -OCH 3 , or -CN. In other embodiments, R 1 is -CN. In still further embodiments, R 1 is -C ⁇ CCH 2 N(CH 3 ) 2 . In one embodiment, R 3 is -CH 3 . Or, R 3 is -OCH 3 . Or, R 3 is -CN.
  • ring A of Formula II is , R 1 is -CF 3 , R 2 is -CH 3 , -CF 3 , -OH, or -CH 2 OH, and R 3 is hydrogen.
  • R 1 is -CN.
  • R 1 is -C ⁇ CCH 2 N(CH 3 ) 2 .
  • R 2 is -CH 3 .
  • R 2 is -CF 3 .
  • R 2 is -OH.
  • R 2 is -CH 2 OH.
  • ring A of Formula II is , R is -CF 3 , R is hydrogen; and R is -CH 3 , -OCH 3 , or -CN.
  • R 1 is -CN. In still further embodiments, R 1 is -C ⁇ CCH 2 N(CH3) 2 . In one embodiment, R 3 is -OCH 3 . Or, R 3 is -CH 3 . Or, R 3 is -CN.
  • ring A is , R 1
  • Formula II is -CF 3 , R 2 is -CH 3 , -CF 3 , -OH, or -CH 2 OH, and R 3 is hydrogen.
  • R 1 is -CN.
  • R 1 is -C ⁇ CCH 2 N(CH3) 2 .
  • R 2 is -CH 3 .
  • R 2 is -CF 3 .
  • R 2 is -OH.
  • R 2 is -CH 2 OH.
  • ring A of Formula II is , R 1 is -CF 3 , R 2 is hydrogen; and R 3 is -CH 3 , -OCH 3 , or -CN.
  • R 1 is -CN. In still further embodiments, R 1 is -C ⁇ CCH 2 N(CH 3 )2. In one embodiment, R 3 is -CH 3 . Or, R 3 is -OCH 3 . Or, R 3 is -CN.
  • ring A of Formula II is , R 1 is -CF 3 , R 2 is -CH 3 , -CF 3 , -OH, or -CH 2 OH, and R 3 is hydrogen.
  • R 1 is -CN.
  • R 1 is -C ⁇ CCH 2 N(CH 3 ) 2 .
  • R 2 is -CH 3 .
  • R 2 is -CF 3 .
  • R 2 is -OH.
  • R 2 is -CH 2 OH.
  • ring A of Formula II is -CF 3 , R 2 is hydrogen; and R 3 is -CH 3 , -OCH 3 , or -CN.
  • R 1 is -CN.
  • R 1 is -C ⁇ CCH 2 N(CH 3 ) 2 .
  • R 3 is -CH 3 .
  • R 3 is -OCH 3 .
  • R 3 is -CN.
  • ring A of Formula II is , R 1 is -CF 3 , R 2 is -CH 3 , -CF 3 , -OH, or -CH 2 OH, and R 3 is hydrogen.
  • R 1 is -CN.
  • R 1 is -C ⁇ CCH 2 N(CH 3 ) 2 .
  • R 2 is -CH 3 .
  • R 2 is -CF 3 .
  • R 2 is -OH.
  • R 2 is -CH 2 OH.
  • the Compound of Formula II is Compound 2, which is known by its chemical name N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2- (trifluoromemyl)phenyl)-4-ox -5-(trifluoromethyl)-l,4-dihydroquinoline-3-carboxamide.
  • Scheme 2-1 depicts a convergent approach to the preparation of compounds of Formula II from substituted benzene derivatives la and 2a.
  • amide formation via coupling of carboxylic acid Id with amine 2c to give a compound of Formula II can be achieved using either 0-(7-azabenzotriazol-l-yl)-N,N,N'N - tetramethyluronium hexafluorophosphate (HATU) and triethylamine in N,N-dimethyl formamide (DMF) or propyl sulfonic acid cyclic anhydride (T3P®) and pyridine in 2- methyltetrahydrofuran.
  • HATU 0-(7-azabenzotriazol-l-yl)-N,N,N'N - tetramethyluronium hexafluorophosphate
  • DMF N,N-dimethyl formamide
  • T3P® propyl sulfonic acid cyclic
  • step b Compound lb is converted to carboxylic acid Id via a three step sequence including intramolecular cyclization upon heating at reflux in Dowtherm or diphenyl ether (step b), followed by removal (if needed) of the blocking halo group (step c) under palladium-catalyzed dehalogenation conditions and acid-or base-catalyzed saponification (step d).
  • step d The order of the deprotection and saponification steps can be reversed; i.e., step c can occur before or after step d, as depicted in Scheme 2-1.
  • aniline derivative 2c can be prepared from nitrobenzene 2a via a three step sequence.
  • DMSO K 2 C0 3 , 80 °C
  • N,N-dimethylprop-2-yn-l -amine Pd(PPh 3 ) 2 Cl 2 , Cul, DMF, TEA, 80 °C
  • Fe, FeS0 4 H 2 0 or Zn, AcOH, H 2 0
  • HATU Et 3 N, DMF or propyl phosphonic acid cyclic anhydride (T3P®), pyridine, 2-methyltetrahydrofuran.
  • Scheme 2-2 depicts the synthesis of compounds of Formula II bearing a propynyl amine side chain.
  • DMSO K 2 C0 3 , heat or CH 3 CN, TEA, heat
  • PGX such as TBDMSC1, base such as imidazole, DMF
  • HATU Et 3 N, DMF or propyl phosphonic acid cyclic anhydride (T3P®), pyridine, 2-methyltetrahydrofuran
  • PG Protecting group
  • X leaving group.
  • Scheme 2-3 depicts the synthesis of a compound of Formula II wherein
  • -' 3 is 7-azabicyclo[2.2.1]heptane, optionally bearing an exo or endo hydroxy group at the 2-position.
  • the hydroxy-substituted adducts (+)-e>ufo-7-azabicyclo[2.2.1]heptan-2-ol, (- )-enrfo-7-azabicyclo[2.2.1]heptan-2-ol, (+)-exo-7-azabicyclo[2.2.1]heptan-2-ol, and (-)-exo-l- azabicyclo[2.2.1]heptan-2-ol can be prepared using procedures as described in Fletcher, S.R., et at, 'Total Synthesis and Determination of the Absolute Configuration of Epibatidine," J. Org. Chem, 59, pp. 1771-1778 (1994). 7-Azabicyclo[2.2.1]heptane itself is commercially available from Tyger Scientific Inc. 324 Stokes Avenue Ewing, NJ
  • Example 2a Diethyl 2-((2-chloro-5-(trifluoromethyl)phenylamino) methylene) malonate (14).
  • Example 2c Ethyl 4-oxo-5-(trifluoromethyl)-lH-quinoline-3-carboxylate (16).
  • Example 2d 4-Oxo-5-(trifluoromethyl)-l,4-dihydroquinoline-3- carboxylic acid (17).
  • Ethyl 4-oxo-5-(trifluoromethyl)-lH-quinoline-3-carboxylate 16 (58 g, 0.2 mol, crude reaction slurry containing Pd/C) was suspended in NaOH (814 mL of 5 M, 4.1 mol) in a 1-L flask with a reflux condenser and heated at 80 °C for 18 h, followed by further heating at 100 °C for 5 h.
  • the reaction was filtered warm through packed Celite to remove Pd/C and the Celite was rinsed with 1 N NaOH.
  • the filtrate was acidified to about pH 1 to obtain a thick, white precipitate.
  • the precipitate was filtered then rinsed with water and cold acetonitrile.
  • Example 2e 8-chloro-4-oxo-5-(trifluoromethyl)-l,4-dihydroquinoline-3- carboxylic acid (15a).
  • Ethyl 8-chloro-4-oxo-5-(trifluoromethyl)-l,4-dihydroquinoline-3-carboxylate (1200 g, 3.754 mol) was charged into a reaction vessel followed by the addition of 2-propanol (1.200L) and water (7.200 L) and stirred. Sodium hydroxide (600.6 g, 7.508 mol) and water (1.200 L) were mixed and allowed to cool to room temperature. The resulting mixture was charged into the reaction vessel and then was heated to 80 °C and stirred for 3.5 h to generate a dark, homogenous mixture.
  • acetic acid (9.599L of 20 %w/v, 31.97 mol) was added via dropping funnel over 45 min.
  • the reaction mixture was cooled with stirring to 22 °C at a rate of 6 °C/h.
  • the resulting solid was filtered and washed with water (3 L) to generate a wet cake (1436 g).
  • the filtrate was dried in a vacuum oven with a nitrogen bleed over Drierite® to generate 8-chloro-4-oxo-5-(trifluoromethyl)-l,4- dihydroquinoline-3-carboxylic acid as a brown solid (1069 g).
  • the 8-chloro-4-oxo-5- (trifluoromethyl)-l,4-dihydroquinoline-3-carboxylic acid was purified by slurrying in 1.5 L methanol and stirring for 6 h. It was then filtered and dried to furnish 968.8 g of purified 8- chloro-4-oxo-5-(trifluoromethyl)- 1 ,4-dihydroquinoline-3-carboxylic acid.
  • Example 2f 4-oxo-5-(trifluoromethyl)-l,4-dihydroquinoline-3-carboxylic acid (17).
  • Example 2g 7-[4-Nitro-3-(trifluoromethyl) phenyl]-7- azabicyclo[2.2.1]heptane (19).
  • the organic layer was concentrated to 4 vol and then the solvent was swapped with cyclohexane until all the EtOAc was removed, and the total volume in the flask was about 4 vol containing cyclohexane.
  • the reaction mixture was heated to 60 °C on a rotary evaporator for 30 min. Then the solution was cooled to room temperature with stirring or rotation for 3 h. When all the solid crystallized, the solution was concentrated to dryness to provide 7-[4-nitro-3-(trifluoromethyl) phenyl]-7- azabicyclo[2.2.1]heptane (19).
  • Example 2h 4-(7-Azabicyclo[2.2.1] heptan-7-yI)-2- (trifluoromethyl)aniline (20).
  • Example 2i Preparation of the hydrochloride salt of 4-(7- azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorometh l)aniline (20-HCl).
  • Example 2j Preparation of Compound 2.
  • reaction flask heated at 65 °C for 10 h under a nitrogen atmosphere. After cooling to room temperature, the reaction was then diluted with ethyl acetate and quenched with saturated Na 2 C0 3 solution (50 mL). The layers were separated, and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with water, dried over Na 2 S04, filtered and
  • Example 2k Preparation of frans-4-( ⁇ butoxycarbonylamino)cyclohexanol (A).
  • reaction mixture was then filtered and the filter cake was washed with water (2 x 8 vol).
  • the product was suction-dried until it was a compact cake.
  • the cake was then dried in a vacuum oven at 35 °C for 24 h giving 830 g of trans-4-(tert- butoxycarbonylamino)cyclohexanol (A) as a crystalline solid.
  • Boc anhydride (3082.6 g) in DCM (1479 mL) was then added to each flask at such a rate as to maintain the temperature at 20 to 30 °C.
  • An ice/water bath was used to control the exotherm and to accelerate the addition, which took approximately 1 to 2 hours. A suspension formed during the addition, and the reaction mixtures were allowed to warm to room temperature and stirred overnight, until the reaction was complete based on the disappearance of the Boc anhydride.
  • Heptane (6 L) was then charged to each flask, and the mixtures were cooled to approximately 0 to 5 °C. Solids were collected from each flask by filtration using the same filter. The combined solids were washed with heptane (6 L) followed by water (8 L).
  • the solids were charged to an appropriately sized crock equipped with a mechanical stirrer. Water (12 L) and heptane (6 L) were added, and the resulting suspension was mechanically stirred for 30 to 60 minutes. The solids were collected by filtration and then washed on a filter with water (8 L) and heptane (8 L), air-dried on a filter for three days, and then dried under vacuum at 30 to 35 °C to a constant weight to provide the product as a white solid.
  • Example 21 Preparation of trans-4-(tert- butoxycarbonylamino)cyclohexylmethanesulfonate (B).
  • Methanesulfonyl chloride (419.0 g, 283.1 mL, 3.658 mol, 1.05 eq) was carefully added dropwise, keeping the temperature of the mixture below 5 °C. After the addition, the mixture was stirred at 0 °C for 3 h, and then gradually warmed to room temperature (17 °C) and stirred overnight (about 15 h). The mixture was quenched with water (6 vol) and stirred for 15 min. Ethyl acetate (EtOAc, 9.000 L, 12 vol) was added and the stirring was continued for 15 min. The stirring was stopped and the mixture was allowed to stand for 10 min, and the aqueous phase was removed.
  • EtOAc Ethyl acetate
  • a jacketed reactor may be used instead of a round bottom flask with a cooling tub and ice bath.
  • Example 2m Preparation of trarts-4-aminocyclohexylmethanesulfonate (C). Method 1.
  • a 50 L three-neck round bottom flask was equipped with a mechanical stirrer, addition funnel and thermocouple and was placed into a cooling tub.
  • To the flask was added tra «i-4-(tert-butoxycarbonylamino)cyclohexylmethanesulfonate (3474 g, 1.0 eq) and DCM (5.9 L) to the flask.
  • the resulting suspension was stirred for 5 to 10 minutes at ambient temperature, and then trifluoroacetic acid (TFA, 5.9 L) was added via addition funnel slowly over 2.5 hours to control the resulting exotherm and rate of gas evolution.
  • TFA trifluoroacetic acid
  • reaction mixture was stirred at room temperature overnight and then cooled to 15 °C to 20 °C using an ice water bath.
  • 2-Methyl tetrahydrofuran (2-MeTHF, 11.8 L) was then added via the addition funnel at a rate to maintain the internal temperature below 25 °C (approximately 1.5 hours).
  • the addition of the first 4-5 L of 2-MeTHF was exothermic.
  • the resulting suspension was stirred for 1 hour.
  • the solids were collected by filtration and then washed with 2-MeTHF (2 x 2.2 L) and then dried under vacuum at ambient temperature to a constant weight to provide the product as a white solid.
  • Example 2n Preparation of 7-azabicyclo[2.2.1]heptane hydrochloride (7a). Method 1.
  • the crude product can also be distilled at about 95 °C to 97 °C and further recrystallized.
  • the product was recovered by fractional distillation at reflux temperature, (approximately 100 °C) with a head temperature of 95 to 98 °C.
  • the pH of each fraction was adjusted to 2 by adding HC1, and concentrated under reduced pressure at 55 °C to leave a thick paste.
  • Acetonitrile (ACN 1.5 L ) was added and the resulting suspension was stirred for 30 minutes and then cooled to 0 to 5 °C for 1 hour.
  • the solids were collected by filtration, washed with cold (0 to 5 °C) ACN (2 x 600 mL), and dried under vacuum at 50 °C to a constant weight.
  • a 22 L three-neck round bottom flask was equipped with a mechanical stirrer, thermocouple, and condenser and placed into a heating mantle.
  • the collected solids (2382 g), methanol (4.7 L) and 2-MeTHF (4.7 L) were added to the flask.
  • the resulting suspension was stirred and heated to reflux ( approximately 65 °C).
  • the reaction flask was transferred to a cooling tub, and the mixture was stirred.
  • 2-MeTHF (4.7 L) was then added via addition funnel over 30 minutes.
  • the resulting suspension was cooled to 0 to 5 °C and stirred at this temperature for 30 minutes.
  • the solids were collected by filtration, washed with cold (0 to 5 °C) 2-MeTHF (2 x 600 mL), and then dried under vacuum at 55 °C to a constant weight.
  • a 12 L three-neck round bottom flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet and condenser was placed into a heating mantle.
  • the crude product (2079 g) and ACN (6.2 L) were added to the flask.
  • the resulting suspension was stirred and heated to reflux (approximately 82 °C) for 30 minutes.
  • the flask was transferred to a cooling tub and the suspension was slowly cooled to 0 to 5 °C and maintained at this temperature for 1 hour.
  • the solids were collected by filtration, washed with cold (0 to 5 °C) ACN (3 x 600 mL), and dried under vacuum at 55 °C to a constant weight affording to provide the product.
  • the invention includes a pharmaceutical composition comprising a Compound of Formula III
  • T is -CH 2 -, -CH 2 CH 2 -, -CF 2 -, -C(CH 3 ) 2 -, or -C(O)-;
  • Ri' is H, Ci-6 aliphatic, halo, CF 3 , CHF 2 , 0(Ci -6 aliphatic);
  • R D1 or R D2 is Z D R 9
  • Z D is a bond, CONH, S0 2 NH, S0 2 N(C,. 6 alkyl), CH 2 NHS0 2 , CH 2 N(CH 3 )S0 2 , CH 2 NHCO, COO, S0 2 , or CO; and
  • R 9 is H, C
  • the compound of Formula III is Compound 3, depicted below, which is also known by its chemical name 3-(6-(l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)ben2oic acid.
  • Compound 3 can be prepared by coupling an acid chloride moiety with an amine moiety according to following Schemes 3-la to 3-3.
  • Scheme 3-la depicts the preparation of l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarbonyl chloride, which is used in Scheme 3-3 to make the amide linkage of Compound 3.
  • the starting material, 2,2-difluorobenzo[d][l,3]dioxole-5-carboxylic acid is commercially available from Saltigo (an affiliate of the Lanxess Corporation). Reduction of the carboxylic acid moiety in 2,2-difluorobenzo[d][l,3]dioxole-5-carboxylic acid to the primary alcohol, followed by conversion to the corresponding chloride using thionyl chloride (SOCl 2 ), provides 5-(chloromethyl)-2,2-difluorobenzo[d][l,3]dioxole, which is subsequently converted to 2-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)acetonitrile using sodium cyanide.
  • Saltigo an affiliate of the Lanxess Corporation
  • Scheme 3-lb provides an alternative synthesis of the requisite acid chloride.
  • the compound 5-bromomethyl- 2,2-difluoro-l,3-benzodioxole is coupled with ethyl cyanoacetate in the presence of a palladium catalyst to form the corresponding alpha cyano ethyl ester.
  • Saponification of the ester moiety to the carboxylic acid gives the cyanoethyl compound.
  • Alkylation of the cyanoethyl compound with l-bromo-2-chloro ethane in the presence of base gives the cyanocyclopropyl compound.
  • Scheme 3-2 depicts the preparation of the requisite tert-butyl 3-(6-amino-3- methylpyridin-2-yl)benzoate, which is coupled with l-(2,2-difluorobenzo[d][l,3]dioxol-5- yl)cyclopropanecarbonyl chloride in Scheme 3-3 to give Compound 3.
  • Palladium-catalyzed coupling of 2-bromo-3-methylpyridine with 3-(tert-butoxycarbonyl)phenylboronic acid gives tert-butyl 3-(3-methylpyridin-2-yl)benzoate, which is subsequently converted to the desired compound.
  • Scheme 3-3 depicts the coupling of l-(2,2-difluorobenzo[d][ 1 ,3]dioxol-5- yl)cyclopropanecarbonyl chloride with tert-butyl 3-(6-amino-3-methylpyridin-2-yl)benzoate using triethyl amine and 4-dimethylaminopyridine to initially provide the tert-butyl ester of Compound 3.
  • Treatment of the tert-butyl ester with an acid such as HC1 gives the HC1 salt of Compound 3, which is typically a crystalline solid.
  • Vitride® sodium bis(2-methoxyethoxy)aluminum hydride
  • NaAlH 2 (OCH2CH 2 OCH3)2] 65 wt% solution in toluene was purchased from Aldrich Chemicals.
  • 2,2-Difluoro-l,3-benzodioxole-5-carboxylic acid was purchased from Saltigo (an affiliate of the Lanxess Corporation).
  • Example 3a (2,2-Difluoro-l,3-benzodioxol-5-yl (-methanol.
  • Example 3b 5-Chloromethyl-2,2-difluoro-l,3-benzodioxole.
  • Example 3c (2,2-Difluoro-l,3-benzodioxoI-5-yl)-acetonitrile.
  • Example 3d Alternate Synthesis of (2,2-difluoro-l,3-benzodioxol-5-yl)-l- eth lacetate-acetonitrile
  • a reactor was purged with nitrogen and charged with toluene (900 mL). The solvent was degassed via nitrogen sparge for no less than 16 hours. To the reactor was then charged Na 3 P0 4 (155.7 g, 949.5 mmol), followed by bis(dibenzylideneacetone) palladium (0) (7.28 g, 12.66 mmol). A 10% w/w solution of rt-butylphosphine in hexanes (51.23 g, 25.32 mmol) was charged over 10 minutes at 23 °C from a nitrogen purged addition funnel.
  • the mixture was allowed to stir for 50 minutes, at which time 5-bromo-2,2-difluoro-l,3-benzodioxole (75 g, 316.5 mmol) was added over 1 minute. After stirring for an additional 50 minutes, the mixture was charged with ethyl cyanoacetate (71.6 g, 633.0 mmol) over 5 minutes, followed by water (4.5 mL) in one portion. The mixture was heated to 70 °C over 40 minutes and analyzed by HPLC every 1 to 2 hours for the percent conversion of the reactant to the product. After complete conversion was observed (typically 100% conversion after 5 to 8 hours), the mixture was cooled to 20 to 25 °C and filtered through a Celite pad.
  • Example 3g l-(2,2-Difiuoro-l,3-benzodioxoI-5-yl)- cyclopropanecarboxylic acid.
  • Example 3h l-(2,2-Difluoro-l,3-benzodioxol-5-yl)-cyclopropanecarbonyI chloride.
  • Example 3i ⁇ -?rt-Butyl-3-(3-methylpyridin-2-yl)benzoate.
  • Example 3j 2-(3-(ter ⁇ Butoxycarbonyl)phenyI)-3-methylpyridine-l-oxide.
  • Example 3m 3-(6-(l-(2,2-Difluorobenzo[d][l,3]dioxol-5-yl)
  • the solid was collected by filtration, washed with water (2 x 0.3 vol), and partially dried on the filter under vacuum.
  • the solid was dried to a constant weigh ( ⁇ 1 % difference) in a vacuum oven at 60 °C with a slight N> bleed to afford 3 «(6-(l-(2,2- di.floorobenzo d][ ,3 jdioxol-5-yI) cyclopropanecarboxamido)-3-methylpyridm-2-yl)benzoic acid » HO as an off-white solid.
  • the invention includes a pharmaceutical composition comprising a Compound of Formula IV
  • R. ⁇ is H or alkyl
  • f is H or CN
  • R 7 is H, -CH 2 CH(OH)CH 2 OH, -Ci i 2 CH 2 N + (CH;0 ⁇ , or ⁇ CH 2 CH 2 OM;
  • R 8 is 1:1, OH, -CH 2 CH(OH)CH 2 OH, -CH 2 OH, or R 7 and R « taken together form
  • the compound of Formula IV is Compound 4, which is known by its chemical name (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3- dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1 H-indol-5- yl)cyclopropanecarboxamide.
  • Compound 4 can be prepared by coupling an acid chloride moiety with an amine moiety according to the schemes below.
  • Scheme 4-1 provides an overview of the synthesis of the amine moiety of Compound 4. From the silyl protected propargyl alcohol shown, conversion to the propargyl chloride followed by formation of the Grignard reagent and subsequent nucleophilic substitution provides ((2,2-dimethylbut-3-ynyloxy)methyl)benzene, which is used in another step of the synthesis.
  • 4-nitro-3-fluoroaniline is first brominated, and then converted to the toluenesulfonic acid salt of (R)-l-(4-amino-2-bromo-5- fluorophenylamino)-3-(benzyloxy)propan-2-ol in a two step process beginning with alkylation of the aniline amino group by (R)-2-(benzyloxymethyl)oxirane, followed by reduction of the nitro group to the corresponding amine.
  • Scheme 4-2 depicts the coupling of the Acid and Amine moieties to produce Compound 4.
  • (R)-l-(5-amino-2-(l-(benzyloxy)-2-methylpropan-2-yl)-6- fluoro-lH-indol-l-yl)-3-(benzyloxy)propan-2-ol is coupled with l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarbonyl chloride to provide the benzyl protected Compound 4.
  • This step can be performed in the presence of a base and a solvent.
  • the base can be an organic base such as triethylamine
  • the solvent can be an organic solvent such as DCM or a mixture of DCM and toluene.
  • the deprotection step can be accomplished using reducing conditions sufficient to remove the benzyl group.
  • the reducing conditions can be hydrogenation conditions such as hydrogen gas in the presence of a palladium catalyst.
  • Example 4a 2-Bromo-5-fluoro-4-nitroaniline.
  • Example 4b p-toluenesulfonic acid salt of (R)-l-((4-amino-2-bromo-5- fluorophenyl)amino)-3-(benzyIoxy)propan-2-oI.
  • the hydrogenator was charged with 5wt% Pt(S)/C (1.5 mol%) and the mixture was stirred under N 2 at 30 °C (internal temperature). The reaction was flushed with N2 followed by hydrogen. The hydrogenator pressure was adjusted to 1 Bar of hydrogen and the mixture was stirred rapidly (>1200 rpm). At the end of the reaction, the catalyst was filtered through a pad of Celite® and washed with dichloromethane (10 vol). The filtrate was concentrated in vacuo. Any remaining isopropyl acetate was chased with dichloromethane (2 vol) and concentrated on a rotavap to dryness.
  • Example 4d (4-(Benzyloxy)-3,3-dimethylbut-l-ynyl)trimethylsi)ane.
  • the aqueous phase (pH 9) was drained off and discarded. The remaining organic phase was washed with water (2 L, 2 vol). The organic phase was concentrated in vacuo using a 22 L rotary evaporator, providing the crude product as an orange oil.
  • Example 4e 4-Benzyloxy-3,3-dimethylbut-l-yne.
  • Example 4f (i?)-l-(4-amino-2-(4-(benzyloxy)-3,3-dimethylbut-l-ynyl)-5- fluorophenylamino)-3-(benzyloxy)propan-2-ol.
  • Example 4g (R)-l-(5-amino-2-(l-(benzyIoxy)-2-methylpropan-2-yl)-6- fluoro-l -indol-l-yI)-3-(benzyloxy)propan-2-ol.
  • Typical yields of Compound 4 from the two-step aeyiatioo / hydrogenolysis procedure range from 68% to 84%, Compound 4 can be recrystalHzed from .IPA-heptane following the same procedure just described,
  • Compound 4 may also be prepared by one of several synthetic routes disclosed in US published patent application US 2009/0131492, incorporated herein by reference.
  • the invention includes crystalline N-[2,4-bis(l,l-dimethylethyl)-5-hydroxyphenyl]-l,4- dihydro-4-oxoquinoline-3-carboxamide (Compound 1) characterized as Form C.
  • Form C is characterized by a peak having a 2-Theta value from about 6.0 to about 6.4 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 7.3 to about 7.7 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 8.1 to about 8.5 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 12.2 to about 12.6 degrees in an XRPD pattern.
  • Form C is characterized by a peak having a 2-Theta value from about 14.4 to about 14.8 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 17.7 to about 18.1 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 20.3 to about 20.7 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value from about 20.7 to about 21.1 degrees in an XRPD pattern.
  • Form C is characterized by a peak having a 2-Theta value of about 6.2 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 7.5 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 8.3 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 12.4 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 14.6 degrees in an XRPD pattern.
  • Form C is characterized by a peak having a 2-Theta value of about 17.9 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 20.5 degrees in an XRPD pattern. In a further embodiment, Form C is characterized by a peak having a 2-Theta value of about 20.9 degrees in an XRPD pattern.
  • Form C is characterized by one or more peaks in an XRPD pattern selected from about 6.2, about 7.5, about 8.3, about 12.4, about 14.6, about 17.9, about 20.5 and about 20.9 degrees as measured on a 2-Theta scale.
  • Form C is characterized by all of the following peaks in an XRPD pattern: about 6.2, about 7.5, about 8.3, about 12.4, about 14.6, about 17.9, about 20.5 and about 20.9 degrees as measured on a 2-Theta scale.
  • Compound 1 Form C can be characterized by the X-Ray powder diffraction pattern depicted in Figure 1-1.
  • peaks as observed in the XRPD pattern are provided in Table 1-la and Table 1-lb below.
  • Each peak described in Table 1-la also has a corresponding peak label (A - H), which are used to describe some embodiments of the invention.
  • Form C can be characterized by an X-Ray powder diffraction pattern having the representative peaks listed in Table 1-lb.
  • Compound 1 Form C can be characterized by an X-Ray powder diffraction pattern having one or more of peaks A, B, C, D, E, F, G and H as described in Table 1-la.
  • Form C is characterized by peak A. In another embodiment, Form C is characterized by peak B. In another embodiment, Form C is characterized by peak B. In another embodiment, Form C is characterized by peak C. In another embodiment, Form C is characterized by peak D. In another embodiment, Form C is characterized by peak E. In another embodiment, Form C is characterized by peak F. In another embodiment, Form C is characterized by peak G. In another embodiment, Form C is characterized by peak H.
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A and B; A and C; A and D; A and E; A and F; A and G; A and H; B and C; B and D; B and E; B and F; B and G; B and H; C and D; C and E; C and F; C and G; C and H; D and E; D and F; D and G; D and H; E and F; E and G; E and H; F and G; F and H; and G and G and G and H.
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B and C; A, B and D; A, B and E; A, B and F; A, B and G; A, B and H; A, C and D; A, C and E; A, C and F; A, C and G; A, C and H; A, D and E; A, D and F; A, D and G; A, D and H; A, E and F; A, E and G; A, E and H; A, F and G; A, F and H; A, G and H; B, C and D; B, C and E; B, C and F; B, C and G; B, C and H; B, D and E; B, D and F; B, D and G; B, D and H; B, E and F; B, E and G; B, E and H; B, F and G; B, F and G; B, E and H; B, F and G
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C and D; A, B, C and E, A, B, C and F; A, B, C and G; A, B, C and H; A, B, D and E; A, B, D and F; A, B, D and G; A, B, D and H; A, B, E and F; A, B, E and G; A, B, E and H; A, B, F and G; A, B, F and H; A, B, G and H; A, C, D and E; A, C, D and F; A, C, D and G; A, C, D and H; A, C, E and F; A, C, E and G; A, C, E and H; A, C, F and G; A, C, F and H; A, C, G and H; A, D, F and G; A, C, F and H; A, C, F
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D and E; A, B, C, D and F; A, B, C, D and G; A, B, C, D and H; A, B, C, E and F; A, B, C, E and G; A, B, C, E and H; A, B, C, F and G; A, B, C, F and H; A, B, C, G and H; A, B, C, E and F; A, B, C, E and G; A, B, C, E and H; A, B, C, F and G; A, B, C, F and H; A, B, C, G and H; A, B, D, E and F; A, B, D, E and G; A, B, D, E and H; A, B, D, F and G; A, B, D, F and H; A, B, D, F and H; A
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D, E and F; A, B, C, D, E and G; A, B, C, D, E and H; A, B, C, D, F and G; A, B, C, D, F and H; A, B, C, D, G and H; A, B, C, E, F and G; A, B, C, E, F and H; A, B, C, E, G and H; A, B, C, F, G and H; A, B, D, E, F and G; A, B, D, E, F and H; A, B, D, E, G and H; A, B, D, F, G and H; A, B, D, F, G and H; A, B, E, F, G and H; A, C, D, E, F and G; A, C, D, E, F and H; A, C, D
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D, E, F and G; A, B, C, D, E, F and H; A, B, C, D, E, G and H; A, B, C, D, F, G and H; A, B, C, E, F, G and H; A, B, D, E, F, G and H; A, C, D, E, F, G and H; and B, C,
  • Form C is characterized by an X-Ray powder diffraction pattern having all of the following peaks as described in Table 1-la: A, B,
  • Compound 1 Form C can be characterized by an X-Ray powder diffraction pattern having one or more of peaks that range in value within ⁇ 0.2 degrees of one or more of the peaks A, B, C, D, E, F, G and H as described in Table 1.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of A.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of B.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of B.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of C.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of D.
  • Form C is characterized by a peak within ⁇ 0.2 degrees of E. In another embodiment, Form C is characterized by a peak within ⁇ 0.2 degrees of F. In another embodiment, Form C is characterized by a peak within ⁇ 0.2 degrees of G. In another embodiment, Form C is characterized by a peak within ⁇ 0.2 degrees of H.
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A and B; A and C; A and D; A and E; A and F; A and G; A and H; B and C; B and D; B and E; B and F; B and G; B and H; C and D; C and E; C and F; C and G; C and H; D and E; D and F; D and G; D and H; E and F; E and G; E and H; F and G; F and H; and G and G and G and G and H, wherein each peak in the group is within ⁇ 0.2 degrees of the corresponding value described in Table 1-la.
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B and C; A, B and D; A, B and E; A, B and F; A, B and G; A, B and H; A, C and D; A, C and E; A, C and F; A, C and G; A, C and H; A, D and E; A, D and F; A, D and G; A, D and H; A, E and F; A, E and G; A, E and H; A, F and G; A, F and H; A, G and H; B, C and D; B, C and E; B, C and F; B, C and G; B, C and H; B, D and E; B, D and F; B, D and G; B, D and H; B, E and F; B, E and G; B, E and H; B, F and G; B, F and G; B, E and H; B, F and G
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C and D; A, B, C and E, A, B, C and F; A, B, C and G; A, B, C and H; A, B, D and E; A, B, D and F; A, B, D and G; A, B, D and H; A, B, E and F; A, B, E and G; A, B, E and H; A, B, F and G; A, B, F and H; A, B, G and H; A, C, D and E; A, C, D and F; A, C, D and G; A, C, D and H; A, C, E and F; A, C, E and G; A, C, E and H; A, C, F and G; A, C, F and H; A, C, G and H; A, D, F and G; A, C, F and H; A, C, F
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D and E; A, B, C, D and F; A, B, C, D and G; A, B, C, D and H; A, B, C, E and F; A, B, C, E and G; A, B, C, E and H; A, B, C, F and G; A, B, C, F and H; A, B, C, G and H; A, B, C, E and F; A, B, C, E and G; A, B, C, E and H; A, B, C, F and G; A, B, C, F and H; A, B, C, G and H; A, B, D, E and F; A, B, D, E and G; A, B, D, E and H; A, B, D, F and G; A, B, D, F and H; A, B, D, F and H; A
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D, E and F; A, B, C, D, E and G; A, B, C, D, E and H; A, B, C, D, F and G; A,
  • B, C, D, F and H A, B, C, D, G and H; A, B, C, E, F and G; A, B, C, E, F and H; A, B, C, E, G and H; A, B, C, F, G and H; A, B, D, E, F and G; A, B, D, E, F and H; A, B, D, E, G and H; A, B, D, F, G and H; A, B, D, F, G and H; A, B, E, F, G and H; A, C, D, E, F and G; A, C, D, E, F and H; A, C, D, E, F and H; A,
  • Form C is characterized by an X-Ray powder diffraction pattern having one of the following groups of peaks as described in Table 1-la: A, B, C, D, E, F and G; A, B, C, D, E, F and H; A, B, C, D, E, G and H; A, B, C, D, F, G and H; A, B, C, E, F, G and H; A, B, D, E, F, G and H; A, C, D, E, F, G and H; and B, C,
  • Form C is characterized by an X-Ray powder diffraction pattern having all of the following peaks as described in Table 1-la: A, B,
  • the structure was solved and refined in a centrosymmetric space group P2j/c using simulated annealing algorithm.
  • the main building block in form C is a dimer composed of two Compound 1 molecules related to each other by a crystallographic inversion center and connected via a pair of hydrogen bonds between the hydroxyl and the amide carbonyl group. These dimers are then further arranged into infinite chains and columns through hydrogen bonding, ⁇ - ⁇ stacking and van der Waals interactions. Two adjacent columns are oriented perpendicular to each other, one along the crystallographic direction a, the other along b. The columns are connected with each other through van der Waals interactions.
  • Form C structure contains two Compound 1 molecular conformations related to one another by rotation around the CI -N 12 bond.
  • a powder pattern calculated from the crystal structure of form C and an experimental powder pattern recorded on powder diffractometer using a flat sample in reflectance mode have been compared.
  • the peak positions are in excellent agreement. Some discrepancies in intensities of some peaks exist and are due to preferred orientation of crystallites in the flat sample.
  • the crystal structure of Compound 1 Form C has a monoclinic lattice type. In another embodiment, the crystal structure of Compound 1 Form C has a P2)/c space group. In another embodiment, the crystal structure of Compound 1 Form C has a monoclinic lattice type and a P2
  • the crystal structure of Compound 1 Form C has the following unit cell dimensions:
  • the invention includes Pharmaceutical compositions including Compound 1 Form C and a pharmaceutically acceptable adjuvant or carrier.
  • Compound 1 Form C can be formulated in a pharmaceutical composition, in some instances, with another therapeutic agent, for example another therapeutic agent for treating cystic fibrosis or a symptom thereof.
  • Methods of treating a CFTR mediated disease, such as cystic fibrosis, in a patient include administering to said patient Compound 1 Form C or a pharmaceutical composition comprising Compound 1 Form C.
  • Compound 1 Form C can be also characterized by an endotherm beginning at 292.78 °C, that plateaus slightly and then peaks at 293.83 °C as measured by DSC ( Figure 1- 2). Further, this endotherm precedes an 85% weight loss, as measured by TGA ( Figure 1-3), which is attributed to chemical degradation.
  • Compound 1 Form C can be characterized by a FT-IR spectrum as depicted in Figure 1-5 and by Raman spectroscopy as depicted by Figure 1-4.
  • Compound 1 Form C can be characterize by solid state NMR spectrum as depicted in Figure 1-6.
  • Compound 1 Form C was prepared by adding an excess of optionally recrystallized Compound 1, prepared as provided in Section II.A.3, into acetonitrile, stirring at 90 °C for 3 days, and cooling to room temperature. The product was harvested by filtration, and the purity of the Compound was confirmed using SSNMR.
  • Isopropyl acetate (DPAc) (10 vol) was added and the solution concentrated at no more than 35 °C (jacket temperature) and no more than 8.0 °C (internal reaction temperature) to 10 vol.
  • the addition of IP Ac and concentration was repeated 2 more times for a total of 3 additions of IP Ac and 4
  • the DSC traces of Form C were obtained using TA Instruments DSC Q2000 equipped with Universal Analysis 2000 software. An amount (3-8 mg) of Compound 1 Form C was weighed into an aluminum pan and sealed with a pinhole lid. The sample was heated from 25 °C to 325 °C at 10 °C/min. The sample exhibited high melting points which is consistent with highly crystalline material.
  • the melting range is about 293.3 to about 294.7 °C. In a further embodiment, the melting range is about 293.8 °C to about 294.2 °C.
  • the onset temperature range is about 292.2 °C to about 293.5 °C. In a further embodiment, the onset temperature range is about 292.7 °C to about 293.0 °C.
  • TGA was conducted on a TA Instruments model Q5000. An amount (3-5 mg) of Compound 1 Form C was placed in a platinum sample pan and heated at 10 °C/min from room temperature to 400 °C. Data were collected by Thermal Advantage Q SeriesTM software and analyzed by Universal Analysis 2000 software.
  • the XRPD patterns were acquired at room temperature in reflection mode using a Bruker D8 Advance diffractometer equipped with a sealed tube copper source and a Vantec-1 detector.
  • the X-ray generator was operating at a voltage of 40 kV and a current of 40 mA.
  • the data were recorded in a ⁇ - ⁇ scanning mode over the range of 3°-40° 2 ⁇ with a step size of 0.014° and the sample spinning at 15 rpm.
  • the C SSNMR spectrum of Compound 1 Form C is includes one or more of the following peaks: 176.5 ppm, 165.3 ppm, 152.0 ppm, 145.8 ppm, 139.3 ppm, 135.4 ppm, 133.3 ppm, 131.8 ppm, 130.2 ppm, 129.4 ppm, 127.7 ppm, 126.8 ppm, 124.8 ppm, 117.0 ppm, 112.2 ppm, 34.5 ppm, 32.3 ppm and 29.6 ppm.
  • the 13 C SSNMR spectrum of Compound 1 Form C includes all of the following peaks: 152.0 ppm, 135.4 ppm, 131.8 ppm, 130.2 ppm, 124.8 ppm, 117.0 ppm and 34.5 ppm.
  • the I3 C SSNMR spectrum of Compound 1 Form C includes all of the following peaks: 152.0 ppm, 135.4 ppm, 131.8 ppm and 117.0 ppm.
  • the 13C SSNMR spectrum of Compound 1 Form C includes all of the following peaks: 135.4 ppm and 131.8 ppm.
  • the SSNMR of Compound 1 Form C includes a peak at about 152.0 ppm, about 135.4, about 131.8 ppm, and about 117 ppm.
  • the invention includes Compound 1 Form C which is characterized by a 13 C SSNMR spectrum having one or more of the following peaks: C, F, H, I, M, N and P, as described by Table 1-14.
  • Form C is characterized by one peak in a 13 C SSNMR spectrum, wherein the peak is selected from C, F, H, I, M, N and P, as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from C and F; C and H; C and N; F and H; F and N; and H and N, as described by Table 1-14.
  • the 1 C SSNMR spectrum includes the peaks I, M and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, F and H; C, H and N; and F, H and N, as described by Table 1-14.
  • the 13 C SSNMR spectrum includes the peaks I, M and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having the following group of peaks: C, F, H and N, as described by Table 1-14.
  • the 13 C SSNMR spectrum includes the peaks I, M and P as described by Table 1-14.
  • Form C is characterized by a l 3 C SSNMR spectrum having a group of peaks selected from C and F; C and H, C and N; C and I; C and M; or C and P, as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from F and H; F and N; F and I; F and M; or F and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from H and N; H and I; H and M; or H and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from N and I; N and M; or N and P as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from I and M; I and P or M and P as described by Table 1-14.
  • Form C is characterized by a l C SSNMR spectrum having a group of peaks selected from C, F and H; C, F and N; C, F and I; C, F and M; or C, F and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, H and N; C, H and I; C, H and M; or C, H and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, N and I; C, N and M; or C, N and P as described by Table 1- 14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, I and M; or C, I and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, M and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from F, H, and N; F, H and I; F, H and M; or F, H and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from F, N and I; F, N and M; or F, N and P as described by Table 1-14.
  • Form C is characterized by a I3 C SSNMR spectrum having a group of peaks selected from F, I and M; or F, I and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from F, M and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, N and I; H, N and M; or H, N and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from H, I and M; or H, I and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, M and P as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from N, I and M; or N, I and P as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a 1 C SSNMR spectrum having a group of peaks selected from N, M and P as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from I, M and P as described by Table 1- 14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, F, H, and N; C, F H, and I; C, F H, and M; or C, F H, and P as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from F, H, N and I; F, H, N and M; or F, H, N and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, N, I and M; H, N, I and P; or H, N, I and C as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from N, I, M and P; N, I, M and C; or N, I, M and F as described by Table 1-14.
  • Form C is characterized by a I3 C SSNMR spectrum having a group of peaks selected from I, M, P and C; I, M, P and F; I, M, P and H as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, H, N and I; C, H, N, and M; or C, H, N, and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, N, I and M; C, N, I and P; or C, N, I and F as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, I, M and P; C, I, M and F; or C, I, M and H as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, M, P and F; C, M, P and H; or C, M, P and N as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from F, N, I and M; F, N, I and P; or F, N, I and C as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from F, I, M and P; F, I, M and C; F, I, M and H; or F, I, M and N as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from F, M, P and C; F, M, P and H; or F, M, P and N as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, I, M and P; H, I, M and C; or H, I, M and F as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from N, M, P and C; N, M, P and F; or N, M, P and H as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from N, M, C and F; or N, M, C and H as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a l C SSNMR spectrum having a group of peaks selected from N, M, F and P as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from N, M, H and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, H, I and P; C, F, I and P; C, F, N and P or F, H, I and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, F, H, N and I; C, F, H, N and M; or C, F, H, N and P; C, F, H, I and M; C, F, H, I and P; C, F, H, M and P; C, F, N, I and M; C, F, N, I and P; C, F, N, M and P; C, H, N, I and M; C, H, N, I and P; C, H, N, M and P; C, H, I, M and P; F, H, N, I and M; F, H, N, I and P; F, H, N, M and P; F, H, I, M and P; F, N, I, M and P or H, N, I, M and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, F, H, N and I; C, F, H, N and M; or C, F, H, N and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, H, N, I and M; or C, H, N, I and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, N, I, M and P; or C, N, I, M and F as described by Table 1-14.
  • a l3 C SSNMR spectrum having a group of peaks selected from C, N, I, M and P; or C, N, I, M and F as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, I, M, P and F; or C, I, M, P and H as described by Table 1- 14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, M, P, F and H; or C, M, P, F and N as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from C, P, F, H and I; or C, P, F, H and M as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from F, H, N, I and M; or F, H, N, I and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from F, N, I, M and P; or F, N, I, M and C as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from F, I, M, C and H; F, I, M, C and N as described by Table 1-14.
  • Form C is characterized by a I3 C SSNMR spectrum having a group of peaks selected from F, M, P, C and H; F, M, P, C and N , N, I and M; or F, H, N, I and P as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from H, N, I M, and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, I M, P and F as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, M, P, C and F as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from H, P, C, F and I as described by Table 1-14.
  • Form C is characterized by a l3 C SSNMR spectrum having a group of peaks selected from C, F, H, N, I, and M; or C, F, H, N, I and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from F, H, N, I, M and P as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from H, N, I, M, P and C as described by Table 1-14.
  • Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from N, I, M, P, C and F as described by Table 1-14. In another embodiment of this aspect, Form C is characterized by a 13 C SSNMR spectrum having a group of peaks selected from M, P, C, F, H and N as described by Table 1-14.
  • Form C is characterized by a C SSNMR spectrum having a group of peaks selected from C, F, H, N, I, and M; C, F, H, N, I and P; C, F, H, N, M and P; C, F, H, I, M and P; C, F, N, I, M and P; C, H, N, I, M and P or F, H, N, I, M and P as described by Table 1-14.
  • Form C is characterized by a 13C SSNMR spectrum having a group of peaks selected from C, F, H, N, I, M and P as described by Table 1-14.
  • the invention includes a compositions comprising various solid forms of Compound 2.
  • Compound 2 is Compound 2 Form A.
  • Compound 2 Form A is characterized by one or more peaks: from about 7.7 to about 8.1 degrees, for example, about 7.9 degrees; from about 11.7 to about 12.1 degrees, for example, about 11.9 degrees; from about 14.2 to about 14.6 degrees, for example, about 14.4 degrees; and about 15.6 to about 16.0 degrees, for example, about 15.8 degrees; in an X-ray powder diffraction obtained using Cu K alpha radiation.
  • Compound 2 Form A is characterized by one or more peaks: from about 7.8 to about 8.0 degrees, for example, about 7.9 degrees; from about 11.8 to about 12.0 degrees, for example, about 11.9 degrees; from about 14.3 to about 14.5 degrees, for example, about 14.4 degrees; and about 15.7 to about 15.9 degrees, for example, about 15.8 degrees; in an X-ray powder diffraction obtained using Cu K alpha radiation.
  • Compound 2 Form A is characterized by one or more peaks from about: 7.7 to about 8.1 degrees, for example, about 7.9 degrees; from about 21.6 to about 22.0 degrees, for example, about 21.8 degrees; and about 23.6 to about 24.0 degrees, for example, about 23.8 degrees; in an X-ray powder diffraction obtained using Cu K alpha radiation.
  • Compound 2 Form A is characterized by one or more peaks from about: 7.8 to about 8.0 degrees, for example, about 7.9 degrees; from about 21.7 to about 21.9 degrees, for example, about 21.8 degrees; and about 23.7 to about 23.9 degrees, for example, about 23.8 degrees; in an X-ray powder diffraction obtained using Cu K alpha radiation.
  • Compound 2 Form A is characterized by one or more of the following peaks measured in degrees in an X-ray powder diffraction pattern: a peak from about 7.7 to about 8.1 degrees (e.g., about 7.9 degrees); a peak from about 9.1 to about 9.5 degrees, (e.g., about 9.3 degrees); a peak from about 11.7 to about 12.1 degrees, (e.g., about 11.9 degrees); a peak from about 14.2 to about 14.6 degrees, (e.g., about 14.4 degrees); a peak from about 14.9 to about 15.3 degrees, (e.g., about 15.1 degrees); a peak from about
  • Compound 2 Form A is characterized by one or more of the following peaks measured in degrees in an X-ray powder diffraction pattern: a peak from about 7.8 to about 8.0 degrees (e.g., about 7.9 degrees); a peak from about 9.2 to about 9.4 degrees, (e.g., about 9.3 degrees); a peak from about 11.8 to about 12.0 degrees, (e.g., about 11.9 degrees); a peak from about 14.3 to about 14.5 degrees, (e.g., about 14.4 degrees); a peak from about 15.0 to about 15.2 degrees, (e.g., about 15.1 degrees); a peak from about 15.7 to about 15.9 degrees, (e.g., about 15.8 degrees); a peak from about 16.9 to about 17.1 degrees, (e.g., about 17.0 degrees); a peak from about 17.6 to about 17.8 degrees, (e.g., about 17.7 degrees); a peak from about 19.2 to about 19.4 degrees, (e.g., about 19.
  • Compound 2 Form A is characterized by a diffraction pattern as provided in Figure 2-1.
  • reaction flask heated at 65 °C for 10 h under a nitrogen atmosphere. After cooling to room temperature, the reaction was then diluted with ethyl acetate and quenched with saturated Na 2 C0 3 solution (50 mL). The layers were separated, and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with water, dried over Na 2 S0 4 , filtered and
  • the Powder X-ray Diffractometer was calibrated using reference standard: 75% Sodalite (Na B AUS O ⁇ Cl) and 25% Silicon
  • FTIR spectra were collected from a Thermo Scientific, Nicolet 6700 FT-IR spectrometer, with smart orbit sampling compartment, diamond window, using Software: Omnic, 7.4. The powder sample was placed directly on the diamond crystal and pressure was added to conform the surface of the sample to the surface of the diamond crystal. The background spectrum was collected and then the sample spectrum was collected. The collection settings were as follows:
  • Table 2-2 provides representative XRPD peaks of Compound 2 Form A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant un composé de formules I et II, éventuellement associé à un composé de formule III et/ou un composé de formule IV. L'invention porte en outre sur des formes solides et des formulations pharmaceutiques de celles-ci, et sur des procédés d'utilisation de ces compositions dans le traitement de maladies médiées par le CFTR, en particulier la fibrose cystique.
PCT/US2011/033689 2010-04-22 2011-04-22 Compositions pharmaceutiques et leurs administrations WO2011133953A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP11718597A EP2560650A1 (fr) 2010-04-22 2011-04-22 Compositions pharmaceutiques et leurs administrations
AU2011242454A AU2011242454A1 (en) 2010-04-22 2011-04-22 Pharmaceutical compositions and administrations thereof
CA2796602A CA2796602A1 (fr) 2010-04-22 2011-04-22 Compositions pharmaceutiques et leurs administrations
NZ603043A NZ603043A (en) 2010-04-22 2011-04-22 Pharmaceutical compositions comprising cftr modulators and administrations thereof
US13/657,345 US20130131107A1 (en) 2010-04-22 2012-10-22 Pharmaceutical compositions and administrations thereof
US14/630,778 US20160022665A2 (en) 2010-04-22 2015-02-25 Pharmaceutical Compositions and Administrations Thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32709910P 2010-04-22 2010-04-22
US61/327,099 2010-04-22
US32950010P 2010-04-29 2010-04-29
US61/329,500 2010-04-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/657,345 Continuation US20130131107A1 (en) 2010-04-22 2012-10-22 Pharmaceutical compositions and administrations thereof

Publications (1)

Publication Number Publication Date
WO2011133953A1 true WO2011133953A1 (fr) 2011-10-27

Family

ID=44312408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033689 WO2011133953A1 (fr) 2010-04-22 2011-04-22 Compositions pharmaceutiques et leurs administrations

Country Status (6)

Country Link
US (2) US20130131107A1 (fr)
EP (1) EP2560650A1 (fr)
AU (1) AU2011242454A1 (fr)
CA (1) CA2796602A1 (fr)
NZ (1) NZ603043A (fr)
WO (1) WO2011133953A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
WO2014086687A1 (fr) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova Correcteur de cftr pour le traitement de troubles génétiques affectant le muscle strié
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2016057730A1 (fr) * 2014-10-07 2016-04-14 Strohmeier Mark Co-cristaux de modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
WO2016151051A1 (fr) * 2015-03-23 2016-09-29 Algipharma As Utilisation d'oligomères d'alginate et de modulateurs de cftr dans le traitement d'états pathologiques associés à un dysfonctionnement du cftr
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US9776968B2 (en) 2007-12-07 2017-10-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2018037350A1 (fr) * 2016-08-23 2018-03-01 Laurus Labs Limited Formes solides de lumacaftor, leur procédé de préparation et leurs compositions pharmaceutiques
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10875846B2 (en) 2019-01-15 2020-12-29 Apotex Inc. Processes for the preparation of Tezacaftor and intermediates thereof
EP3835297A1 (fr) * 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthèse et intermédiaires de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2yl)-1h-indol-5-yl) cyclopropanecarboxamide
US11248010B2 (en) 2016-04-07 2022-02-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
WO2022232634A1 (fr) 2021-04-29 2022-11-03 Novartis Ag Chimères ciblant la désubiquitinase et procédés associés
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR20080053297A (ko) 2005-08-11 2008-06-12 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유종 트랜스막 전도도 조정자의 조절자
EP2016065B1 (fr) 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated Dérivés de la 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide et composés similaires en tant que modulateurs des transporteurs de cassettes de liaison de l'atp pour le traitement de la fibrose cystique
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2696298C (fr) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
EP3012250B1 (fr) 2007-11-16 2017-11-08 Vertex Pharmaceuticals Incorporated Modulateurs d'isoquinoleine de transporteurs de cassette de liaison a l'atp
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
JP2012504143A (ja) * 2008-09-29 2012-02-16 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
ES2858351T3 (es) * 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producción de compuestos de cicloalquilcaraboxamido-indol
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2872122A1 (fr) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration
US10759721B2 (en) 2015-09-25 2020-09-01 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR potentiators
IL274763B2 (en) 2017-12-01 2024-01-01 Vertex Pharma Methods for making cystic fibrosis transmembrane conductance modulator modulators
US10022233B1 (en) * 2017-12-04 2018-07-17 Duke University Orthopedic implant for sustained drug release

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20030144257A1 (en) 2000-08-05 2003-07-31 Keith Biggadike Novel anti-inflammatory androstane derivative compositions
US20040006237A1 (en) 2001-11-14 2004-01-08 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
US20040105820A1 (en) 1997-09-29 2004-06-03 Weers Jeffry G. Phospholipid-based powders for inhalation
WO2005075435A1 (fr) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de type cassette de liaison a l'atp
WO2006002421A2 (fr) 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
WO2007056341A1 (fr) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated MODULATEURS HÉTÉROCYCLIQUES DE TRANSPORTEURS À CASSETTE LIANT l’ATP
WO2007079139A2 (fr) * 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine-3-carboxamide
WO2007117715A2 (fr) * 2006-04-07 2007-10-18 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassettes de liaison de l'atp
WO2009023509A2 (fr) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
WO2009038683A2 (fr) * 2007-09-14 2009-03-26 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20090105272A1 (en) 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
US20090131492A1 (en) 2006-04-07 2009-05-21 Ruah Sara S Hadida Indole derivatives as CFTR modulators
WO2009073757A1 (fr) * 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Formes solides d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
WO2009076141A2 (fr) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
US7553855B2 (en) 2006-05-12 2009-06-30 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20090246820A1 (en) 2005-12-27 2009-10-01 Singh Ashvani K Compounds useful in cftr assays and methods therewith
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
WO2010037066A2 (fr) * 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
WO2010048564A1 (fr) * 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
WO2010048526A2 (fr) * 2008-10-23 2010-04-29 Vertex Pharmaceuticals, Incorporated Modulateurs de régulateur de conductance transmembranaire de mucoviscidose
WO2010054138A2 (fr) * 2008-11-06 2010-05-14 Vertex Pharmaceuticals, Incorporated Modulateurs des transporteurs de la cassette de liaison à l’atp
WO2010053471A1 (fr) * 2008-11-06 2010-05-14 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs à cassette de liaison à l'atp
US20100130547A1 (en) 2008-10-23 2010-05-27 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
US20100184739A1 (en) 2004-06-24 2010-07-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100267768A1 (en) 2009-03-20 2010-10-21 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20110065928A1 (en) 2009-09-17 2011-03-17 Vertex Pharmaceuticals Incorporated Process for Preparing Azabicyclic Compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20040105820A1 (en) 1997-09-29 2004-06-03 Weers Jeffry G. Phospholipid-based powders for inhalation
US20030144257A1 (en) 2000-08-05 2003-07-31 Keith Biggadike Novel anti-inflammatory androstane derivative compositions
US20040006237A1 (en) 2001-11-14 2004-01-08 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
WO2005075435A1 (fr) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de type cassette de liaison a l'atp
US20100184739A1 (en) 2004-06-24 2010-07-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
WO2006002421A2 (fr) 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
US7495103B2 (en) 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7741321B2 (en) 2005-11-08 2010-06-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20080306062A1 (en) 2005-11-08 2008-12-11 Hadida Ruah Sara S Modulators of atp-binding cassette transporters
WO2007056341A1 (fr) * 2005-11-08 2007-05-18 Vertex Pharmaceuticals Incorporated MODULATEURS HÉTÉROCYCLIQUES DE TRANSPORTEURS À CASSETTE LIANT l’ATP
US7659268B2 (en) 2005-11-08 2010-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105272A1 (en) 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
US20090246820A1 (en) 2005-12-27 2009-10-01 Singh Ashvani K Compounds useful in cftr assays and methods therewith
WO2007079139A2 (fr) * 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine-3-carboxamide
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7776905B2 (en) 2006-04-07 2010-08-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090131492A1 (en) 2006-04-07 2009-05-21 Ruah Sara S Hadida Indole derivatives as CFTR modulators
WO2007117715A2 (fr) * 2006-04-07 2007-10-18 Vertex Pharmaceuticals Incorporated Modulateurs des transporteurs de cassettes de liaison de l'atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7553855B2 (en) 2006-05-12 2009-06-30 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2009023509A2 (fr) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
WO2009038683A2 (fr) * 2007-09-14 2009-03-26 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20090099230A1 (en) 2007-09-14 2009-04-16 Demattei John Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2009073757A1 (fr) * 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Formes solides d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
US20090170905A1 (en) 2007-12-07 2009-07-02 Ali Keshavarz-Shokri Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2009076141A2 (fr) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
US20090176839A1 (en) 2007-12-07 2009-07-09 Ali Keshavarz-Shokri Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010037066A2 (fr) * 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Unités posologiques d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque
US20100087490A1 (en) 2008-09-29 2010-04-08 Vertex Pharmaceuticals Incorporated Dosage Units of 3-(6-(1-(2,2-Difluorobenzo[D] [1,3] Dioxol-5-YL) Cyclopropanecarboxamido)-3-Methylpyridin-2-YL)Benzoic Acid
US20100130547A1 (en) 2008-10-23 2010-05-27 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide
US20100113508A1 (en) 2008-10-23 2010-05-06 Vertex Pharmaceuticals, Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
WO2010048526A2 (fr) * 2008-10-23 2010-04-29 Vertex Pharmaceuticals, Incorporated Modulateurs de régulateur de conductance transmembranaire de mucoviscidose
WO2010048564A1 (fr) * 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
WO2010053471A1 (fr) * 2008-11-06 2010-05-14 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs à cassette de liaison à l'atp
WO2010054138A2 (fr) * 2008-11-06 2010-05-14 Vertex Pharmaceuticals, Incorporated Modulateurs des transporteurs de la cassette de liaison à l’atp
US20100267768A1 (en) 2009-03-20 2010-10-21 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20110065928A1 (en) 2009-09-17 2011-03-17 Vertex Pharmaceuticals Incorporated Process for Preparing Azabicyclic Compounds

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Perry's Chemical Engineering Handbook", 1984, MCGRAW-HILL BOOK CO.
"Remington: The Science and Practice of Pharmacy", 2003, LIPPINCOTT WILLIAMS & WILKINS
"The Handbook of Pharmaceutical Excipients", 2003, AMERICAN PHARMACEUTICALS ASSOCIATION
ANSEL ET AL.: "Pharmaceutical Dosage Forms And Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369
DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528
DALEMANS, W., BARBRY, P., CHAMPIGNY, G., JALLAT, S., DOTT, K., DREYER, D., CRYSTAL, R.G., PAVIRANI, A., LECOCQ, J-P., LAZDUNSKI, M, NATURE, vol. 354, 1991, pages 526 - 528
DEAN, M. ET AL., CELL, vol. 61, 1990
E. W. MARTIN: "Remington's Pharmaceutical Sciences", 1980, MACK PUBLISHING CO.
FLETCHER, S.R. ET AL.: "Total Synthesis and Determination of the Absolute Configuration of Epibatidine", J. ORG. CHEM, vol. 59, 1994, pages 1771 - 1778
GALIETTA, L.J.V., LANTERO, S., GAZZOLO, A., SACCO, O., ROMANO, L., ROSSI, G.A., ZEGARRA-MORAN, O., IN VITRO CELL. DEV. BIOL., vol. 34, 1998, pages 478 - 481
GIBSON: "Pharmaceutical Preformulation And Formulation", 2001, CRC PRESS
GONZALEZ, J. E., K. OADES ET AL.: "Cell-based assays and instrumentation for screening ion-channel targets", DRUG DISCOV TODAY, vol. 4, no. 9, 1999, pages 431 - 439
GONZALEZ, J. E., R. Y. TSIEN: "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer", CHEM BIOL, vol. 4, no. 4, 1997, pages 269 - 77
GONZALEZ, J. E., R. Y. TSIEN: "Voltage sensing by fluorescence resonance energy transfer in single cells", BIOPHYS J, vol. 69, no. 4, 1995, pages 1272 - 80
GREENE, WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
GREGORY, R. J. ET AL., NATURE, vol. 347, 1990, pages 382 - 386
HWANG, T. C. ET AL., J. GEN. PHYSIOL., vol. 111, no. 3, 1998, pages 477 - 90
J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
JONES ANDREW M ET AL: "Emerging Treatments in Cystic Fibrosis", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 69, no. 14, 1 January 2009 (2009-01-01), pages 1903 - 1910, XP008134754, ISSN: 0012-6667, DOI: DOI:10.2165/11318500-000000000-00000 *
KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451
KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080
LEE R. CHOO-KANG, PAMELA L.: "Zeitlin, Type I, ll, III, N, and V cystic fibrosis Transmembrane Conductance Regulator Defects and Opportunities of Therapy", CURRENT OPINION IN PULMONARY MEDICINE, vol. 6, 2000, pages 521 - 529
MARSHALL: "Atomization and Spray-Drying", CHEM. ENG. PROG. MONOGR. SERIES 2, vol. 50, 1954
P.J.KOCIENSKI: "Protecting Groups", 1994, THIEME
PASYK, FOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50
QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727
RAE, J., COOPER, K., GATES, P., WATSKY, M., J. NEUROSCI. METHODS, vol. 37, 1991, pages 15 - 26
RICH, D. P. ET AL., NATURE, vol. 347, 1990, pages 358 - 362
RIORDAN, J. R. ET AL., SCIENCE, vol. 245, 1989, pages 1066 - 1073
SHELDRICK, G.M., ACTA CRYST., vol. A64, 2008, pages 112 - 122
SHELDRICK,G.M., ACTA CRYST., vol. A64, 2008, pages 112 - 122

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10662192B2 (en) 2004-06-24 2020-05-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11084804B2 (en) 2005-11-08 2021-08-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9931334B2 (en) 2005-12-28 2018-04-03 Vertex Pharmaceuticals Incorporated Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11291662B2 (en) 2005-12-28 2022-04-05 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9670163B2 (en) 2005-12-28 2017-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10537565B2 (en) 2005-12-28 2020-01-21 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9725440B2 (en) 2007-05-09 2017-08-08 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US9776968B2 (en) 2007-12-07 2017-10-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US10597384B2 (en) 2007-12-07 2020-03-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9840499B2 (en) 2007-12-07 2017-12-12 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US12065432B2 (en) 2007-12-07 2024-08-20 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9751890B2 (en) 2008-02-28 2017-09-05 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
US11564916B2 (en) 2008-08-13 2023-01-31 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US10646481B2 (en) 2008-08-13 2020-05-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US9751839B2 (en) 2009-03-20 2017-09-05 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP4253381A3 (fr) * 2010-03-25 2023-11-01 Vertex Pharmaceuticals Incorporated Formes solides de (r)-1-(2,2-difluorobenzo[d [1,3!d dioxol-5-yl)-n-(1-(2,3-dihydroxypranyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
EP3835297A1 (fr) * 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthèse et intermédiaires de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2yl)-1h-indol-5-yl) cyclopropanecarboxamide
US10076513B2 (en) 2010-04-07 2018-09-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US11052075B2 (en) 2010-04-07 2021-07-06 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10272046B2 (en) 2012-02-27 2019-04-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11752106B2 (en) 2012-02-27 2023-09-12 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US11147770B2 (en) 2012-02-27 2021-10-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2014086687A1 (fr) 2012-12-03 2014-06-12 Universita' Degli Studi Di Padova Correcteur de cftr pour le traitement de troubles génétiques affectant le muscle strié
CN103044263A (zh) * 2013-01-14 2013-04-17 中国药科大学 一种治疗囊性纤维化药物的中间体的制备方法
US8937178B2 (en) 2013-03-13 2015-01-20 Flatley Discovery Lab Phthalazinone compounds and methods for the treatment of cystic fibrosis
US9790215B2 (en) 2013-03-13 2017-10-17 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
RU2718044C2 (ru) * 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11992553B2 (en) 2014-08-29 2024-05-28 Algipharma As Inhalable powder formulations of alginate oligomers
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016057730A1 (fr) * 2014-10-07 2016-04-14 Strohmeier Mark Co-cristaux de modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
AU2015330923B2 (en) * 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10751363B2 (en) 2015-03-23 2020-08-25 Algipharma As Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
AU2016236172B2 (en) * 2015-03-23 2021-07-01 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfunction
WO2016151051A1 (fr) * 2015-03-23 2016-09-29 Algipharma As Utilisation d'oligomères d'alginate et de modulateurs de cftr dans le traitement d'états pathologiques associés à un dysfonctionnement du cftr
US11413306B2 (en) 2015-10-06 2022-08-16 Algipharma As Alginate oligomers for the treatment or prevention of microbial overgrowth in the intestinal tract
US11248010B2 (en) 2016-04-07 2022-02-15 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
WO2018037350A1 (fr) * 2016-08-23 2018-03-01 Laurus Labs Limited Formes solides de lumacaftor, leur procédé de préparation et leurs compositions pharmaceutiques
US10875846B2 (en) 2019-01-15 2020-12-29 Apotex Inc. Processes for the preparation of Tezacaftor and intermediates thereof
WO2022232634A1 (fr) 2021-04-29 2022-11-03 Novartis Ag Chimères ciblant la désubiquitinase et procédés associés

Also Published As

Publication number Publication date
CA2796602A1 (fr) 2011-10-27
US20160022665A2 (en) 2016-01-28
EP2560650A1 (fr) 2013-02-27
NZ603043A (en) 2015-02-27
US20130131107A1 (en) 2013-05-23
AU2011242454A1 (en) 2012-11-08
US20150164883A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
AU2018226453B2 (en) Pharmaceutical Compositions and Administrations Thereof
US20150164883A1 (en) Pharmaceutical compositions and administrations thereof
US20160022664A2 (en) Pharmaceutical Compositions and Administrations Thereof
US20200338063A1 (en) Pharmaceutical compositions for the treatment of cftr mediated diseases
AU2014349010C1 (en) Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
AU2011293658B2 (en) Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
AU2018208694A1 (en) Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methypropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
US20160200684A2 (en) Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11718597

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2796602

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011718597

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011718597

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011242454

Country of ref document: AU

Date of ref document: 20110422

Kind code of ref document: A